<?xml version='1.0' encoding='UTF-8'?>
<uniprot xmlns="http://uniprot.org/uniprot" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://uniprot.org/uniprot http://www.uniprot.org/support/docs/uniprot.xsd">
<entry dataset="Swiss-Prot" created="1988-01-01" modified="2017-05-10" version="236">
<accession>P06213</accession>
<accession>Q17RW0</accession>
<accession>Q59H98</accession>
<accession>Q9UCB7</accession>
<accession>Q9UCB8</accession>
<accession>Q9UCB9</accession>
<name>INSR_HUMAN</name>
<protein>
<recommendedName>
<fullName>Insulin receptor</fullName>
<shortName>IR</shortName>
<ecNumber>2.7.10.1</ecNumber>
</recommendedName>
<cdAntigenName>CD220</cdAntigenName>
<component>
<recommendedName>
<fullName>Insulin receptor subunit alpha</fullName>
</recommendedName>
</component>
<component>
<recommendedName>
<fullName>Insulin receptor subunit beta</fullName>
</recommendedName>
</component>
</protein>
<gene>
<name type="primary">INSR</name>
</gene>
<organism>
<name type="scientific">Homo sapiens</name>
<name type="common">Human</name>
<dbReference type="NCBI Taxonomy" id="9606"/>
<lineage>
<taxon>Eukaryota</taxon>
<taxon>Metazoa</taxon>
<taxon>Chordata</taxon>
<taxon>Craniata</taxon>
<taxon>Vertebrata</taxon>
<taxon>Euteleostomi</taxon>
<taxon>Mammalia</taxon>
<taxon>Eutheria</taxon>
<taxon>Euarchontoglires</taxon>
<taxon>Primates</taxon>
<taxon>Haplorrhini</taxon>
<taxon>Catarrhini</taxon>
<taxon>Hominidae</taxon>
<taxon>Homo</taxon>
</lineage>
</organism>
<reference key="1">
<citation type="journal article" date="1985" name="Cell" volume="40" first="747" last="758">
<title>The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signalling.</title>
<authorList>
<person name="Ebina Y."/>
<person name="Ellis L."/>
<person name="Jarnagin K."/>
<person name="Edery M."/>
<person name="Graf L."/>
<person name="Clauser E."/>
<person name="Ou J.-H."/>
<person name="Masiarz F."/>
<person name="Kan Y.W."/>
<person name="Goldfine I.D."/>
<person name="Roth R.A."/>
<person name="Rutter W.J."/>
</authorList>
<dbReference type="PubMed" id="2859121"/>
<dbReference type="DOI" id="10.1016/0092-8674(85)90334-4"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG)</scope>
<scope>VARIANTS GLY-2; HIS-171; THR-448 AND LYS-492</scope>
</reference>
<reference key="2">
<citation type="journal article" date="1985" name="Nature" volume="313" first="756" last="761">
<title>Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes.</title>
<authorList>
<person name="Ullrich A."/>
<person name="Bell J.R."/>
<person name="Chen E.Y."/>
<person name="Herrera R."/>
<person name="Petruzzelli L.M."/>
<person name="Dull T.J."/>
<person name="Gray A."/>
<person name="Coussens L."/>
<person name="Liao Y.-C."/>
<person name="Tsubokawa M."/>
<person name="Mason A."/>
<person name="Seeburg P.H."/>
<person name="Grunfeld C."/>
<person name="Rosen O.M."/>
<person name="Ramachandran J."/>
</authorList>
<dbReference type="PubMed" id="2983222"/>
<dbReference type="DOI" id="10.1038/313756a0"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT)</scope>
<scope>PROTEIN SEQUENCE OF 28-49 AND 763-782</scope>
<scope>GLYCOSYLATION AT ASN-43 AND ASN-769</scope>
<scope>VARIANT GLY-2</scope>
</reference>
<reference key="3">
<citation type="submission" date="1985-07" db="EMBL/GenBank/DDBJ databases">
<authorList>
<person name="Chen E.Y."/>
</authorList>
</citation>
<scope>SEQUENCE REVISION TO 899-900</scope>
</reference>
<reference key="4">
<citation type="journal article" date="1990" name="Diabetes" volume="39" first="123" last="128">
<title>Human insulin-receptor gene. Partial sequence and amplification of exons by polymerase chain reaction.</title>
<authorList>
<person name="Seino S."/>
<person name="Seino M."/>
<person name="Bell G.I."/>
</authorList>
<dbReference type="PubMed" id="2210055"/>
<dbReference type="DOI" id="10.2337/diacare.39.1.123"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA]</scope>
<scope>VARIANT GLY-2</scope>
<source>
<tissue>Fetal liver</tissue>
</source>
</reference>
<reference key="5">
<citation type="journal article" date="2004" name="Nature" volume="428" first="529" last="535">
<title>The DNA sequence and biology of human chromosome 19.</title>
<authorList>
<person name="Grimwood J."/>
<person name="Gordon L.A."/>
<person name="Olsen A.S."/>
<person name="Terry A."/>
<person name="Schmutz J."/>
<person name="Lamerdin J.E."/>
<person name="Hellsten U."/>
<person name="Goodstein D."/>
<person name="Couronne O."/>
<person name="Tran-Gyamfi M."/>
<person name="Aerts A."/>
<person name="Altherr M."/>
<person name="Ashworth L."/>
<person name="Bajorek E."/>
<person name="Black S."/>
<person name="Branscomb E."/>
<person name="Caenepeel S."/>
<person name="Carrano A.V."/>
<person name="Caoile C."/>
<person name="Chan Y.M."/>
<person name="Christensen M."/>
<person name="Cleland C.A."/>
<person name="Copeland A."/>
<person name="Dalin E."/>
<person name="Dehal P."/>
<person name="Denys M."/>
<person name="Detter J.C."/>
<person name="Escobar J."/>
<person name="Flowers D."/>
<person name="Fotopulos D."/>
<person name="Garcia C."/>
<person name="Georgescu A.M."/>
<person name="Glavina T."/>
<person name="Gomez M."/>
<person name="Gonzales E."/>
<person name="Groza M."/>
<person name="Hammon N."/>
<person name="Hawkins T."/>
<person name="Haydu L."/>
<person name="Ho I."/>
<person name="Huang W."/>
<person name="Israni S."/>
<person name="Jett J."/>
<person name="Kadner K."/>
<person name="Kimball H."/>
<person name="Kobayashi A."/>
<person name="Larionov V."/>
<person name="Leem S.-H."/>
<person name="Lopez F."/>
<person name="Lou Y."/>
<person name="Lowry S."/>
<person name="Malfatti S."/>
<person name="Martinez D."/>
<person name="McCready P.M."/>
<person name="Medina C."/>
<person name="Morgan J."/>
<person name="Nelson K."/>
<person name="Nolan M."/>
<person name="Ovcharenko I."/>
<person name="Pitluck S."/>
<person name="Pollard M."/>
<person name="Popkie A.P."/>
<person name="Predki P."/>
<person name="Quan G."/>
<person name="Ramirez L."/>
<person name="Rash S."/>
<person name="Retterer J."/>
<person name="Rodriguez A."/>
<person name="Rogers S."/>
<person name="Salamov A."/>
<person name="Salazar A."/>
<person name="She X."/>
<person name="Smith D."/>
<person name="Slezak T."/>
<person name="Solovyev V."/>
<person name="Thayer N."/>
<person name="Tice H."/>
<person name="Tsai M."/>
<person name="Ustaszewska A."/>
<person name="Vo N."/>
<person name="Wagner M."/>
<person name="Wheeler J."/>
<person name="Wu K."/>
<person name="Xie G."/>
<person name="Yang J."/>
<person name="Dubchak I."/>
<person name="Furey T.S."/>
<person name="DeJong P."/>
<person name="Dickson M."/>
<person name="Gordon D."/>
<person name="Eichler E.E."/>
<person name="Pennacchio L.A."/>
<person name="Richardson P."/>
<person name="Stubbs L."/>
<person name="Rokhsar D.S."/>
<person name="Myers R.M."/>
<person name="Rubin E.M."/>
<person name="Lucas S.M."/>
</authorList>
<dbReference type="PubMed" id="15057824"/>
<dbReference type="DOI" id="10.1038/nature02399"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]</scope>
</reference>
<reference key="6">
<citation type="journal article" date="2004" name="Genome Res." volume="14" first="2121" last="2127">
<title>The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).</title>
<authorList>
<consortium name="The MGC Project Team"/>
</authorList>
<dbReference type="PubMed" id="15489334"/>
<dbReference type="DOI" id="10.1101/gr.2596504"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM SHORT)</scope>
<scope>VARIANT GLY-2</scope>
</reference>
<reference key="7">
<citation type="journal article" date="1987" name="J. Biol. Chem." volume="262" first="16186" last="16191">
<title>Characterization of the promoter region of the human insulin receptor gene. Evidence for promoter activity.</title>
<authorList>
<person name="Araki E."/>
<person name="Shimada F."/>
<person name="Uzawa H."/>
<person name="Mori M."/>
<person name="Ebina Y."/>
</authorList>
<dbReference type="PubMed" id="3680248"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33</scope>
<scope>VARIANT GLY-2</scope>
</reference>
<reference key="8">
<citation type="journal article" date="1989" name="Diabetes Res. Clin. Pract." volume="7" first="S31" last="S33">
<title>Characterization of the promoter region of the human insulin receptor gene.</title>
<authorList>
<person name="Araki E."/>
<person name="Shimada F."/>
<person name="Fukushima H."/>
<person name="Mori M."/>
<person name="Shichiri M."/>
<person name="Ebina Y."/>
</authorList>
<dbReference type="PubMed" id="2806055"/>
<dbReference type="DOI" id="10.1016/0168-8227(89)90085-5"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33</scope>
<scope>VARIANT GLY-2</scope>
</reference>
<reference key="9">
<citation type="journal article" date="1989" name="J. Biol. Chem." volume="264" first="16238" last="16245">
<title>Characterization of the promoter region and 3' end of the human insulin receptor gene.</title>
<authorList>
<person name="Tewari D.S."/>
<person name="Cook D.M."/>
<person name="Taub R."/>
</authorList>
<dbReference type="PubMed" id="2777789"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33</scope>
<scope>VARIANT GLY-2</scope>
</reference>
<reference key="10">
<citation type="journal article" date="1990" name="Mol. Endocrinol." volume="4" first="647" last="656">
<title>Structural and functional analysis of the insulin receptor promoter.</title>
<authorList>
<person name="McKeon C."/>
<person name="Moncada V."/>
<person name="Pham T."/>
<person name="Salvatore P."/>
<person name="Kadowaki T."/>
<person name="Accili D."/>
<person name="Taylor S.I."/>
</authorList>
<dbReference type="PubMed" id="2280779"/>
<dbReference type="DOI" id="10.1210/mend-4-4-647"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33</scope>
<scope>VARIANT GLY-2</scope>
<source>
<tissue>Skin fibroblast</tissue>
</source>
</reference>
<reference key="11">
<citation type="journal article" date="1990" name="J. Biol. Chem." volume="265" first="18673" last="18681">
<title>Substructural analysis of the insulin receptor by microsequence analyses of limited tryptic fragments isolated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis in the absence or presence of dithiothreitol.</title>
<authorList>
<person name="Xu Q.-Y."/>
<person name="Paxton R.J."/>
<person name="Fujita-Yamaguchi Y."/>
</authorList>
<dbReference type="PubMed" id="2211730"/>
</citation>
<scope>PROTEIN SEQUENCE OF 28-44; 192-205; 299-314; 610-627 AND 763-780</scope>
<scope>ENZYME REGULATION</scope>
<scope>SUBUNIT</scope>
<source>
<tissue>Placenta</tissue>
</source>
</reference>
<reference key="12">
<citation type="journal article" date="1993" name="Biochemistry" volume="32" first="13531" last="13536">
<title>Characterization of human placental insulin-like growth factor-I/insulin hybrid receptors by protein microsequencing and purification.</title>
<authorList>
<person name="Kasuya J."/>
<person name="Paz I.B."/>
<person name="Maddux B.A."/>
<person name="Goldfine I.D."/>
<person name="Hefta S.A."/>
<person name="Fujita-Yamaguchi Y."/>
</authorList>
<dbReference type="PubMed" id="8257688"/>
<dbReference type="DOI" id="10.1021/bi00212a019"/>
</citation>
<scope>PROTEIN SEQUENCE OF 28-45 AND 763-782</scope>
<scope>FUNCTION</scope>
<scope>FORMATION OF A HYBRID RECEPTOR WITH IGF1R</scope>
<source>
<tissue>Placenta</tissue>
</source>
</reference>
<reference key="13">
<citation type="submission" date="2005-03" db="EMBL/GenBank/DDBJ databases">
<authorList>
<person name="Totoki Y."/>
<person name="Toyoda A."/>
<person name="Takeda T."/>
<person name="Sakaki Y."/>
<person name="Tanaka A."/>
<person name="Yokoyama S."/>
<person name="Ohara O."/>
<person name="Nagase T."/>
<person name="Kikuno R.F."/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 538-1382 (ISOFORM SHORT)</scope>
<source>
<tissue>Brain</tissue>
</source>
</reference>
<reference key="14">
<citation type="journal article" date="1989" name="Biochem. Biophys. Res. Commun." volume="159" first="312" last="316">
<title>Alternative splicing of human insulin receptor messenger RNA.</title>
<authorList>
<person name="Seino S."/>
<person name="Bell G.I."/>
</authorList>
<dbReference type="PubMed" id="2538124"/>
<dbReference type="DOI" id="10.1016/0006-291X(89)92439-X"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] OF 728-772 (ISOFORM LONG)</scope>
<scope>ALTERNATIVE SPLICING</scope>
</reference>
<reference key="15">
<citation type="journal article" date="1990" name="EMBO J." volume="9" first="2409" last="2413">
<title>Functionally distinct insulin receptors generated by tissue-specific alternative splicing.</title>
<authorList>
<person name="Mosthaf L."/>
<person name="Grako K."/>
<person name="Dull T.J."/>
<person name="Coussens L."/>
<person name="Ullrich A."/>
<person name="McClain D.A."/>
</authorList>
<dbReference type="PubMed" id="2369896"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] OF 744-823 (ISOFORM LONG)</scope>
<scope>TISSUE SPECIFICITY</scope>
<scope>LIGAND-BINDING</scope>
<scope>AUTOPHOSPHORYLATION</scope>
</reference>
<reference key="16">
<citation type="journal article" date="1989" name="Diabetes" volume="38" first="737" last="743">
<title>Molecular and clinical characterization of an insertional polymorphism of the insulin-receptor gene.</title>
<authorList>
<person name="Elbein S.C."/>
</authorList>
<dbReference type="PubMed" id="2566545"/>
<dbReference type="DOI" id="10.2337/diab.38.6.737"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 895-1085</scope>
</reference>
<reference key="17">
<citation type="journal article" date="1988" name="Biochem. J." volume="252" first="607" last="615">
<title>Studies on the autophosphorylation of the insulin receptor from human placenta. Analysis of the sites phosphorylated by two-dimensional peptide mapping.</title>
<authorList>
<person name="Tavare J.M."/>
<person name="Denton R.M."/>
</authorList>
<dbReference type="PubMed" id="3166375"/>
<dbReference type="DOI" id="10.1042/bj2520607"/>
</citation>
<scope>PROTEIN SEQUENCE OF 927-956; 981-1019; 1182-1194 AND 1352-1369</scope>
<scope>PHOSPHORYLATION AT TYR-999; TYR-1355 AND TYR-1361</scope>
<source>
<tissue>Placenta</tissue>
</source>
</reference>
<reference key="18">
<citation type="journal article" date="1989" name="Science" volume="245" first="63" last="66">
<title>Human diabetes associated with a deletion of the tyrosine kinase domain of the insulin receptor.</title>
<authorList>
<person name="Taira M."/>
<person name="Taira M."/>
<person name="Hashimoto N."/>
<person name="Shimada F."/>
<person name="Suzuki Y."/>
<person name="Kanatsuka A."/>
<person name="Nakamura F."/>
<person name="Ebina Y."/>
<person name="Tatibana M."/>
<person name="Makino H."/>
</authorList>
<dbReference type="PubMed" id="2544997"/>
<dbReference type="DOI" id="10.1126/science.2544997"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1006-1123</scope>
</reference>
<reference key="19">
<citation type="journal article" date="1987" name="Protein Seq. Data Anal." volume="1" first="3" last="6">
<title>Partial amino acid sequence analyses of human placental insulin receptor.</title>
<authorList>
<person name="Fujita-Yamaguchi Y."/>
<person name="Hawke D."/>
<person name="Shively J.E."/>
<person name="Choi S."/>
</authorList>
<dbReference type="PubMed" id="3447155"/>
</citation>
<scope>PARTIAL PROTEIN SEQUENCE</scope>
</reference>
<reference key="20">
<citation type="journal article" date="1987" name="Proc. Natl. Acad. Sci. U.S.A." volume="84" first="704" last="708">
<title>Replacement of lysine residue 1030 in the putative ATP-binding region of the insulin receptor abolishes insulin- and antibody-stimulated glucose uptake and receptor kinase activity.</title>
<authorList>
<person name="Ebina Y."/>
<person name="Araki E."/>
<person name="Taira M."/>
<person name="Shimada F."/>
<person name="Mori M."/>
<person name="Craik C.S."/>
<person name="Siddle K."/>
<person name="Pierce S.B."/>
<person name="Roth R.A."/>
<person name="Rutter W.J."/>
</authorList>
<dbReference type="PubMed" id="3101064"/>
<dbReference type="DOI" id="10.1073/pnas.84.3.704"/>
</citation>
<scope>MUTAGENESIS OF LYS-1057</scope>
</reference>
<reference key="21">
<citation type="journal article" date="1988" name="Cell" volume="54" first="641" last="649">
<title>Mutation of the insulin receptor at tyrosine 960 inhibits signal transmission but does not affect its tyrosine kinase activity.</title>
<authorList>
<person name="White M.F."/>
<person name="Livingston J.N."/>
<person name="Backer J.M."/>
<person name="Lauris V."/>
<person name="Dull T.J."/>
<person name="Ullrich A."/>
<person name="Kahn C.R."/>
</authorList>
<dbReference type="PubMed" id="2842060"/>
<dbReference type="DOI" id="10.1016/S0092-8674(88)80008-4"/>
</citation>
<scope>MUTAGENESIS OF TYR-999</scope>
</reference>
<reference key="22">
<citation type="journal article" date="1992" name="Biochem. Biophys. Res. Commun." volume="186" first="244" last="250">
<title>Analysis of the order of autophosphorylation of human insulin receptor tyrosines 1158, 1162 and 1163.</title>
<authorList>
<person name="Dickens M."/>
<person name="Tavare J.M."/>
</authorList>
<dbReference type="PubMed" id="1321605"/>
<dbReference type="DOI" id="10.1016/S0006-291X(05)80799-5"/>
</citation>
<scope>AUTOPHOSPHORYLATION</scope>
</reference>
<reference key="23">
<citation type="journal article" date="1992" name="Biochem. Biophys. Res. Commun." volume="189" first="650" last="653">
<title>Identification of a disulfide bridge connecting the alpha-subunits of the extracellular domain of the insulin receptor.</title>
<authorList>
<person name="Schaeffer L."/>
<person name="Ljungqvist L."/>
</authorList>
<dbReference type="PubMed" id="1472036"/>
<dbReference type="DOI" id="10.1016/0006-291X(92)92250-2"/>
</citation>
<scope>DISULFIDE BONDS</scope>
<scope>GLYCOSYLATION AT ASN-541</scope>
</reference>
<reference key="24">
<citation type="journal article" date="1993" name="Biochem. J." volume="290" first="419" last="426">
<title>Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity.</title>
<authorList>
<person name="Soos M.A."/>
<person name="Field C.E."/>
<person name="Siddle K."/>
</authorList>
<dbReference type="PubMed" id="8452530"/>
<dbReference type="DOI" id="10.1042/bj2900419"/>
</citation>
<scope>FUNCTION</scope>
<scope>FORMATION OF A HYBRID RECEPTOR WITH IGF1R</scope>
</reference>
<reference key="25">
<citation type="journal article" date="1994" name="J. Biol. Chem." volume="269" first="29" last="32">
<title>Direct activation of the phosphatidylinositol 3'-kinase by the insulin receptor.</title>
<authorList>
<person name="Van Horn D.J."/>
<person name="Myers M.G. Jr."/>
<person name="Backer J.M."/>
</authorList>
<dbReference type="PubMed" id="8276809"/>
</citation>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH PIK3R1</scope>
</reference>
<reference key="26">
<citation type="journal article" date="1995" name="J. Biol. Chem." volume="270" first="23258" last="23262">
<title>Distinct modes of interaction of SHC and insulin receptor substrate-1 with the insulin receptor NPEY region via non-SH2 domains.</title>
<authorList>
<person name="He W."/>
<person name="O'Neill T.J."/>
<person name="Gustafson T.A."/>
</authorList>
<dbReference type="PubMed" id="7559478"/>
<dbReference type="DOI" id="10.1074/jbc.270.40.23258"/>
</citation>
<scope>INTERACTION WITH IRS1 AND SHC1</scope>
<scope>MUTAGENESIS OF LEU-991; TYR-992; ASN-996; 996-ASN-PRO-997; PRO-997; TYR-999; LEU-1000 AND ALA-1002</scope>
</reference>
<reference key="27">
<citation type="journal article" date="1995" name="Mol. Cell. Biol." volume="15" first="2500" last="2508">
<title>Phosphotyrosine-dependent interaction of SHC and insulin receptor substrate 1 with the NPEY motif of the insulin receptor via a novel non-SH2 domain.</title>
<authorList>
<person name="Gustafson T.A."/>
<person name="He W."/>
<person name="Craparo A."/>
<person name="Schaub C.D."/>
<person name="O'Neill T.J."/>
</authorList>
<dbReference type="PubMed" id="7537849"/>
<dbReference type="DOI" id="10.1128/MCB.15.5.2500"/>
</citation>
<scope>INTERACTION WITH IRS1; SHC1 AND PIK3R1</scope>
<scope>MUTAGENESIS OF ASN-996; PRO-997; GLU-998; TYR-999 AND LYS-1057</scope>
</reference>
<reference key="28">
<citation type="journal article" date="1997" name="Biochem. J." volume="327" first="209" last="215">
<title>Insulin receptor/IGF-I receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting.</title>
<authorList>
<person name="Bailyes E.M."/>
<person name="Nave B.T."/>
<person name="Soos M.A."/>
<person name="Orr S.R."/>
<person name="Hayward A.C."/>
<person name="Siddle K."/>
</authorList>
<dbReference type="PubMed" id="9355755"/>
<dbReference type="DOI" id="10.1042/bj3270209"/>
</citation>
<scope>FORMATION OF A HYBRID RECEPTOR WITH IGF1R</scope>
<scope>TISSUE SPECIFICITY</scope>
</reference>
<reference key="29">
<citation type="journal article" date="1997" name="Eur. J. Biochem." volume="250" first="411" last="417">
<title>Identification of Stat 5B as a substrate of the insulin receptor.</title>
<authorList>
<person name="Sawka-Verhelle D."/>
<person name="Filloux C."/>
<person name="Tartare-Deckert S."/>
<person name="Mothe I."/>
<person name="Van Obberghen E."/>
</authorList>
<dbReference type="PubMed" id="9428692"/>
<dbReference type="DOI" id="10.1111/j.1432-1033.1997.0411a.x"/>
</citation>
<scope>FUNCTION IN PHOSPHORYLATION OF STAT5B</scope>
<scope>MUTAGENESIS OF TYR-999</scope>
<scope>INTERACTION WITH STAT5B; IRS1 AND IRS2</scope>
</reference>
<reference key="30">
<citation type="journal article" date="1997" name="J. Biol. Chem." volume="272" first="448" last="457">
<title>Functional association between the insulin receptor and the transmembrane protein-tyrosine phosphatase LAR in intact cells.</title>
<authorList>
<person name="Ahmad F."/>
<person name="Goldstein B.J."/>
</authorList>
<dbReference type="PubMed" id="8995282"/>
<dbReference type="DOI" id="10.1074/jbc.272.11.7519"/>
</citation>
<scope>INTERACTION WITH PTPRF</scope>
</reference>
<reference key="31">
<citation type="journal article" date="1997" name="J. Biol. Chem." volume="272" first="1639" last="1645">
<title>Protein-tyrosine phosphatase 1B complexes with the insulin receptor in vivo and is tyrosine-phosphorylated in the presence of insulin.</title>
<authorList>
<person name="Bandyopadhyay D."/>
<person name="Kusari A."/>
<person name="Kenner K.A."/>
<person name="Liu F."/>
<person name="Chernoff J."/>
<person name="Gustafson T.A."/>
<person name="Kusari J."/>
</authorList>
<dbReference type="PubMed" id="8999839"/>
<dbReference type="DOI" id="10.1074/jbc.272.3.1639"/>
</citation>
<scope>INTERACTION WITH PTPRE</scope>
<scope>DEPHOSPHORYLATION BY PTPRE</scope>
</reference>
<reference key="32">
<citation type="journal article" date="1997" name="Mol. Cell. Endocrinol." volume="129" first="121" last="126">
<title>Distribution of insulin/insulin-like growth factor-I hybrid receptors in human tissues.</title>
<authorList>
<person name="Federici M."/>
<person name="Porzio O."/>
<person name="Zucaro L."/>
<person name="Fusco A."/>
<person name="Borboni P."/>
<person name="Lauro D."/>
<person name="Sesti G."/>
</authorList>
<dbReference type="PubMed" id="9202395"/>
<dbReference type="DOI" id="10.1016/S0303-7207(97)04050-1"/>
</citation>
<scope>FORMATION OF A HYBRID RECEPTOR WITH IGF1R</scope>
<scope>TISSUE SPECIFICITY</scope>
</reference>
<reference key="33">
<citation type="journal article" date="1999" name="Mol. Cell. Biol." volume="19" first="3278" last="3288">
<title>Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells.</title>
<authorList>
<person name="Frasca F."/>
<person name="Pandini G."/>
<person name="Scalia P."/>
<person name="Sciacca L."/>
<person name="Mineo R."/>
<person name="Costantino A."/>
<person name="Goldfine I.D."/>
<person name="Belfiore A."/>
<person name="Vigneri R."/>
</authorList>
<dbReference type="PubMed" id="10207053"/>
<dbReference type="DOI" id="10.1128/MCB.19.5.3278"/>
</citation>
<scope>TISSUE SPECIFICITY</scope>
<scope>FUNCTION AS RECEPTOR FOR IGFII (ISOFORM SHORT)</scope>
</reference>
<reference key="34">
<citation type="journal article" date="2000" name="Diabetes" volume="49" first="13" last="19">
<title>Membrane glycoprotein PC-1 inhibition of insulin receptor function occurs via direct interaction with the receptor alpha-subunit.</title>
<authorList>
<person name="Maddux B.A."/>
<person name="Goldfine I.D."/>
</authorList>
<dbReference type="PubMed" id="10615944"/>
<dbReference type="DOI" id="10.2337/diabetes.49.1.13"/>
</citation>
<scope>INTERACTION WITH ENPP1</scope>
<scope>ENZYME REGULATION</scope>
</reference>
<reference key="35">
<citation type="journal article" date="2000" name="J. Biol. Chem." volume="275" first="9792" last="9796">
<title>Identification of tyrosine phosphatases that dephosphorylate the insulin receptor. A brute force approach based on 'substrate-trapping' mutants.</title>
<authorList>
<person name="Waelchli S."/>
<person name="Curchod M.L."/>
<person name="Gobert R.P."/>
<person name="Arkinstall S."/>
<person name="Hooft van Huijsduijnen R."/>
</authorList>
<dbReference type="PubMed" id="10734133"/>
<dbReference type="DOI" id="10.1074/jbc.275.13.9792"/>
</citation>
<scope>PHOSPHORYLATION</scope>
<scope>DEPHOSPHORYLATION BY PTPN1 AND PTPN2</scope>
</reference>
<reference key="36">
<citation type="journal article" date="2000" name="Oncogene" volume="19" first="2052" last="2059">
<title>Evidence for an interaction between the insulin receptor and Grb7. A role for two of its binding domains, PIR and SH2.</title>
<authorList>
<person name="Kasus-Jacobi A."/>
<person name="Bereziat V."/>
<person name="Perdereau D."/>
<person name="Girard J."/>
<person name="Burnol A.F."/>
</authorList>
<dbReference type="PubMed" id="10803466"/>
<dbReference type="DOI" id="10.1038/sj.onc.1203469"/>
</citation>
<scope>INTERACTION WITH GRB7</scope>
<scope>MUTAGENESIS OF LYS-1057; TYR-1189 AND TYR-1190</scope>
</reference>
<reference key="37">
<citation type="journal article" date="2001" name="Genomics" volume="74" first="12" last="20">
<title>Cloning, mapping, and characterization of the human sorbin and SH3 domain containing 1 (SORBS1) gene: a protein associated with c-Abl during insulin signaling in the hepatoma cell line Hep3B.</title>
<authorList>
<person name="Lin W.-H."/>
<person name="Huang C.-J."/>
<person name="Liu M.-W."/>
<person name="Chang H.-M."/>
<person name="Chen Y.-J."/>
<person name="Tai T.-Y."/>
<person name="Chuang L.-M."/>
</authorList>
<dbReference type="PubMed" id="11374898"/>
<dbReference type="DOI" id="10.1006/geno.2001.6541"/>
</citation>
<scope>INTERACTION WITH SORBS1</scope>
</reference>
<reference key="38">
<citation type="journal article" date="2001" name="J. Biol. Chem." volume="276" first="46933" last="46940">
<title>Multiple activation loop conformations and their regulatory properties in the insulin receptor's kinase domain.</title>
<authorList>
<person name="Ablooglu A.J."/>
<person name="Frankel M."/>
<person name="Rusinova E."/>
<person name="Ross J.B."/>
<person name="Kohanski R.A."/>
</authorList>
<dbReference type="PubMed" id="11598120"/>
<dbReference type="DOI" id="10.1074/jbc.M107236200"/>
</citation>
<scope>CATALYTIC ACTIVITY</scope>
<scope>MUTAGENESIS OF ASP-1159 AND ARG-1163</scope>
<scope>ENZYME REGULATION</scope>
</reference>
<reference key="39">
<citation type="journal article" date="2002" name="J. Biol. Chem." volume="277" first="4845" last="4852">
<title>Inhibition of insulin receptor catalytic activity by the molecular adapter Grb14.</title>
<authorList>
<person name="Bereziat V."/>
<person name="Kasus-Jacobi A."/>
<person name="Perdereau D."/>
<person name="Cariou B."/>
<person name="Girard J."/>
<person name="Burnol A.F."/>
</authorList>
<dbReference type="PubMed" id="11726652"/>
<dbReference type="DOI" id="10.1074/jbc.M106574200"/>
</citation>
<scope>INTERACTION WITH GRB14</scope>
<scope>ENZYME REGULATION</scope>
</reference>
<reference key="40">
<citation type="journal article" date="2002" name="J. Biol. Chem." volume="277" first="39684" last="39695">
<title>Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved.</title>
<authorList>
<person name="Pandini G."/>
<person name="Frasca F."/>
<person name="Mineo R."/>
<person name="Sciacca L."/>
<person name="Vigneri R."/>
<person name="Belfiore A."/>
</authorList>
<dbReference type="PubMed" id="12138094"/>
<dbReference type="DOI" id="10.1074/jbc.M202766200"/>
</citation>
<scope>FUNCTION</scope>
<scope>FORMATION OF A HYBRID RECEPTOR WITH IGF1R</scope>
</reference>
<reference key="41">
<citation type="journal article" date="2003" name="J. Biol. Chem." volume="278" first="8460" last="8467">
<title>Grb10 inhibits insulin-stimulated insulin receptor substrate (IRS)-phosphatidylinositol 3-kinase/Akt signaling pathway by disrupting the association of IRS-1/IRS-2 with the insulin receptor.</title>
<authorList>
<person name="Wick K.R."/>
<person name="Werner E.D."/>
<person name="Langlais P."/>
<person name="Ramos F.J."/>
<person name="Dong L.Q."/>
<person name="Shoelson S.E."/>
<person name="Liu F."/>
</authorList>
<dbReference type="PubMed" id="12493740"/>
<dbReference type="DOI" id="10.1074/jbc.M208518200"/>
</citation>
<scope>INTERACTION WITH GRB10</scope>
<scope>ENZYME REGULATION</scope>
</reference>
<reference key="42">
<citation type="journal article" date="2003" name="Mol. Cell. Biol." volume="23" first="2096" last="2108">
<title>Regulation of insulin receptor signaling by the protein tyrosine phosphatase TCPTP.</title>
<authorList>
<person name="Galic S."/>
<person name="Klingler-Hoffmann M."/>
<person name="Fodero-Tavoletti M.T."/>
<person name="Puryer M.A."/>
<person name="Meng T.C."/>
<person name="Tonks N.K."/>
<person name="Tiganis T."/>
</authorList>
<dbReference type="PubMed" id="12612081"/>
<dbReference type="DOI" id="10.1128/MCB.23.6.2096-2108.2003"/>
</citation>
<scope>PHOSPHORYLATION</scope>
<scope>DEPHOSPHORYLATION BY PTPN2</scope>
</reference>
<reference key="43">
<citation type="journal article" date="2005" name="J. Clin. Invest." volume="115" first="2462" last="2471">
<title>Deletion of SOCS7 leads to enhanced insulin action and enlarged islets of Langerhans.</title>
<authorList>
<person name="Banks A.S."/>
<person name="Li J."/>
<person name="McKeag L."/>
<person name="Hribal M.L."/>
<person name="Kashiwada M."/>
<person name="Accili D."/>
<person name="Rothman P.B."/>
</authorList>
<dbReference type="PubMed" id="16127460"/>
<dbReference type="DOI" id="10.1172/JCI23853"/>
</citation>
<scope>INTERACTION WITH SOCS7</scope>
</reference>
<reference key="44">
<citation type="journal article" date="2005" name="Mol. Cell. Biol." volume="25" first="10803" last="10814">
<title>Tyrosine phosphorylation of phosphoinositide-dependent kinase 1 by the insulin receptor is necessary for insulin metabolic signaling.</title>
<authorList>
<person name="Fiory F."/>
<person name="Alberobello A.T."/>
<person name="Miele C."/>
<person name="Oriente F."/>
<person name="Esposito I."/>
<person name="Corbo V."/>
<person name="Ruvo M."/>
<person name="Tizzano B."/>
<person name="Rasmussen T.E."/>
<person name="Gammeltoft S."/>
<person name="Formisano P."/>
<person name="Beguinot F."/>
</authorList>
<dbReference type="PubMed" id="16314505"/>
<dbReference type="DOI" id="10.1128/MCB.25.24.10803-10814.2005"/>
</citation>
<scope>FUNCTION IN PHOSPHORYLATION OF PDPK1</scope>
<scope>INTERACTION WITH PDPK1</scope>
</reference>
<reference key="45">
<citation type="journal article" date="2005" name="Zool. Sci." volume="22" first="169" last="175">
<title>Receptor-type protein tyrosine phosphatase epsilon (PTPepsilonM) is a negative regulator of insulin signaling in primary hepatocytes and liver.</title>
<authorList>
<person name="Nakagawa Y."/>
<person name="Aoki N."/>
<person name="Aoyama K."/>
<person name="Shimizu H."/>
<person name="Shimano H."/>
<person name="Yamada N."/>
<person name="Miyazaki H."/>
</authorList>
<dbReference type="PubMed" id="15738637"/>
<dbReference type="DOI" id="10.2108/zsj.22.169"/>
</citation>
<scope>DEPHOSPHORYLATION BY PTPRE</scope>
</reference>
<reference key="46">
<citation type="journal article" date="2006" name="J. Biol. Chem." volume="281" first="25869" last="25874">
<title>Hybrid receptors formed by insulin receptor (IR) and insulin-like growth factor I receptor (IGF-IR) have low insulin and high IGF-1 affinity irrespective of the IR splice variant.</title>
<authorList>
<person name="Slaaby R."/>
<person name="Schaeffer L."/>
<person name="Lautrup-Larsen I."/>
<person name="Andersen A.S."/>
<person name="Shaw A.C."/>
<person name="Mathiasen I.S."/>
<person name="Brandt J."/>
</authorList>
<dbReference type="PubMed" id="16831875"/>
<dbReference type="DOI" id="10.1074/jbc.M605189200"/>
</citation>
<scope>FUNCTION</scope>
<scope>FORMATION OF A HYBRID RECEPTOR WITH IGF1R</scope>
</reference>
<reference key="47">
<citation type="journal article" date="2006" name="Nat. Rev. Mol. Cell Biol." volume="7" first="85" last="96">
<title>Critical nodes in signalling pathways: insights into insulin action.</title>
<authorList>
<person name="Taniguchi C.M."/>
<person name="Emanuelli B."/>
<person name="Kahn C.R."/>
</authorList>
<dbReference type="PubMed" id="16493415"/>
<dbReference type="DOI" id="10.1038/nrg1767"/>
</citation>
<scope>REVIEW ON SIGNALING PATHWAYS</scope>
</reference>
<reference key="48">
<citation type="journal article" date="2007" name="Cell. Mol. Life Sci." volume="64" first="873" last="891">
<title>Regulation of insulin receptor function.</title>
<authorList>
<person name="Youngren J.F."/>
</authorList>
<dbReference type="PubMed" id="17347799"/>
<dbReference type="DOI" id="10.1007/s00018-007-6359-9"/>
</citation>
<scope>REVIEW ON REGULATION OF INSR FUNCTION</scope>
</reference>
<reference key="49">
<citation type="journal article" date="2008" name="Proc. Natl. Acad. Sci. U.S.A." volume="105" first="10762" last="10767">
<title>A quantitative atlas of mitotic phosphorylation.</title>
<authorList>
<person name="Dephoure N."/>
<person name="Zhou C."/>
<person name="Villen J."/>
<person name="Beausoleil S.A."/>
<person name="Bakalarski C.E."/>
<person name="Elledge S.J."/>
<person name="Gygi S.P."/>
</authorList>
<dbReference type="PubMed" id="18669648"/>
<dbReference type="DOI" id="10.1073/pnas.0805139105"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-400; TYR-401 AND SER-407</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
</source>
</reference>
<reference key="50">
<citation type="journal article" date="2009" name="Biochemistry" volume="48" first="5492" last="5500">
<title>A thermodynamic study of ligand binding to the first three domains of the human insulin receptor: relationship between the receptor alpha-chain C-terminal peptide and the site 1 insulin mimetic peptides.</title>
<authorList>
<person name="Menting J.G."/>
<person name="Ward C.W."/>
<person name="Margetts M.B."/>
<person name="Lawrence M.C."/>
</authorList>
<dbReference type="PubMed" id="19459609"/>
<dbReference type="DOI" id="10.1021/bi900261q"/>
</citation>
<scope>DOMAIN</scope>
<scope>INSULIN-BINDING SITE</scope>
</reference>
<reference key="51">
<citation type="journal article" date="2009" name="J. Proteome Res." volume="8" first="651" last="661">
<title>Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry.</title>
<authorList>
<person name="Chen R."/>
<person name="Jiang X."/>
<person name="Sun D."/>
<person name="Han G."/>
<person name="Wang F."/>
<person name="Ye M."/>
<person name="Wang L."/>
<person name="Zou H."/>
</authorList>
<dbReference type="PubMed" id="19159218"/>
<dbReference type="DOI" id="10.1021/pr8008012"/>
</citation>
<scope>GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-242 AND ASN-541</scope>
<source>
<tissue>Liver</tissue>
</source>
</reference>
<reference key="52">
<citation type="journal article" date="2009" name="Mol. Cell. Proteomics" volume="8" first="1751" last="1764">
<title>Large-scale proteomics analysis of the human kinome.</title>
<authorList>
<person name="Oppermann F.S."/>
<person name="Gnad F."/>
<person name="Olsen J.V."/>
<person name="Hornberger R."/>
<person name="Greff Z."/>
<person name="Keri G."/>
<person name="Mann M."/>
<person name="Daub H."/>
</authorList>
<dbReference type="PubMed" id="19369195"/>
<dbReference type="DOI" id="10.1074/mcp.M800588-MCP200"/>
</citation>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
</reference>
<reference key="53">
<citation type="journal article" date="2009" name="Nat. Biotechnol." volume="27" first="378" last="386">
<title>Mass-spectrometric identification and relative quantification of N-linked cell surface glycoproteins.</title>
<authorList>
<person name="Wollscheid B."/>
<person name="Bausch-Fluck D."/>
<person name="Henderson C."/>
<person name="O'Brien R."/>
<person name="Bibel M."/>
<person name="Schiess R."/>
<person name="Aebersold R."/>
<person name="Watts J.D."/>
</authorList>
<dbReference type="PubMed" id="19349973"/>
<dbReference type="DOI" id="10.1038/nbt.1532"/>
</citation>
<scope>GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-445 AND ASN-920</scope>
<source>
<tissue>Leukemic T-cell</tissue>
</source>
</reference>
<reference key="54">
<citation type="journal article" date="2014" name="J. Proteomics" volume="96" first="253" last="262">
<title>An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.</title>
<authorList>
<person name="Bian Y."/>
<person name="Song C."/>
<person name="Cheng K."/>
<person name="Dong M."/>
<person name="Wang F."/>
<person name="Huang J."/>
<person name="Sun D."/>
<person name="Wang L."/>
<person name="Ye M."/>
<person name="Zou H."/>
</authorList>
<dbReference type="PubMed" id="24275569"/>
<dbReference type="DOI" id="10.1016/j.jprot.2013.11.014"/>
</citation>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Liver</tissue>
</source>
</reference>
<reference key="55">
<citation type="journal article" date="2016" name="Nat. Struct. Mol. Biol." volume="23" first="916" last="920">
<title>A minimized human insulin-receptor-binding motif revealed in a Conus geographus venom insulin.</title>
<authorList>
<person name="Menting J.G."/>
<person name="Gajewiak J."/>
<person name="MacRaild C.A."/>
<person name="Chou D.H."/>
<person name="Disotuar M.M."/>
<person name="Smith N.A."/>
<person name="Miller C."/>
<person name="Erchegyi J."/>
<person name="Rivier J.E."/>
<person name="Olivera B.M."/>
<person name="Forbes B.E."/>
<person name="Smith B.J."/>
<person name="Norton R.S."/>
<person name="Safavi-Hemami H."/>
<person name="Lawrence M.C."/>
</authorList>
<dbReference type="PubMed" id="27617429"/>
<dbReference type="DOI" id="10.1038/nsmb.3292"/>
</citation>
<scope>SUBUNIT</scope>
</reference>
<reference key="56">
<citation type="journal article" date="1994" name="Nature" volume="372" first="746" last="754">
<title>Crystal structure of the tyrosine kinase domain of the human insulin receptor.</title>
<authorList>
<person name="Hubbard S.R."/>
<person name="Wei L."/>
<person name="Ellis L."/>
<person name="Hendrickson W.A."/>
</authorList>
<dbReference type="PubMed" id="7997262"/>
<dbReference type="DOI" id="10.1038/372746a0"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 1005-1310</scope>
</reference>
<reference key="57">
<citation type="journal article" date="1997" name="EMBO J." volume="16" first="5572" last="5581">
<title>Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog.</title>
<authorList>
<person name="Hubbard S.R."/>
</authorList>
<dbReference type="PubMed" id="9312016"/>
<dbReference type="DOI" id="10.1093/emboj/16.18.5572"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH ATP ANALOG AND IRS1 PEPTIDE</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>ACTIVE SITE</scope>
<scope>AUTOPHOSPHORYLATION</scope>
<scope>PHOSPHORYLATION AT TYR-1185; TYR-1189 AND TYR-1190</scope>
</reference>
<reference key="58">
<citation type="journal article" date="2001" name="J. Biol. Chem." volume="276" first="10049" last="10055">
<title>Crystallographic and solution studies of an activation loop mutant of the insulin receptor tyrosine kinase: insights into kinase mechanism.</title>
<authorList>
<person name="Till J.H."/>
<person name="Ablooglu A.J."/>
<person name="Frankel M."/>
<person name="Bishop S.M."/>
<person name="Kohanski R.A."/>
<person name="Hubbard S.R."/>
</authorList>
<dbReference type="PubMed" id="11124964"/>
<dbReference type="DOI" id="10.1074/jbc.M010161200"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH ATP ANALOG</scope>
<scope>CATALYTIC ACTIVITY</scope>
</reference>
<reference key="59">
<citation type="journal article" date="2003" name="J. Biol. Chem." volume="278" first="26007" last="26014">
<title>Structural and biochemical evidence for an autoinhibitory role for tyrosine 984 in the juxtamembrane region of the insulin receptor.</title>
<authorList>
<person name="Li S."/>
<person name="Covino N.D."/>
<person name="Stein E.G."/>
<person name="Till J.H."/>
<person name="Hubbard S.R."/>
</authorList>
<dbReference type="PubMed" id="12707268"/>
<dbReference type="DOI" id="10.1074/jbc.M302425200"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 1005-1298 OF MUTANT ASN-1159</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>AUTOPHOSPHORYLATION</scope>
<scope>MUTAGENESIS OF TYR-1011</scope>
</reference>
<reference key="60">
<citation type="journal article" date="2003" name="Mol. Cell" volume="12" first="1379" last="1389">
<title>Structural basis for recruitment of the adaptor protein APS to the activated insulin receptor.</title>
<authorList>
<person name="Hu J."/>
<person name="Liu J."/>
<person name="Ghirlando R."/>
<person name="Saltiel A.R."/>
<person name="Hubbard S.R."/>
</authorList>
<dbReference type="PubMed" id="14690593"/>
<dbReference type="DOI" id="10.1016/S1097-2765(03)00487-8"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH ATP ANALOG AND SH2B2</scope>
<scope>PHOSPHORYLATION AT TYR-1185; TYR-1189 AND TYR-1190</scope>
</reference>
<reference key="61">
<citation type="journal article" date="2005" name="Mol. Cell" volume="20" first="325" last="333">
<title>Structural basis for inhibition of the insulin receptor by the adaptor protein Grb14.</title>
<authorList>
<person name="Depetris R.S."/>
<person name="Hu J."/>
<person name="Gimpelevich I."/>
<person name="Holt L.J."/>
<person name="Daly R.J."/>
<person name="Hubbard S.R."/>
</authorList>
<dbReference type="PubMed" id="16246733"/>
<dbReference type="DOI" id="10.1016/j.molcel.2005.09.001"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (3.20 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH GRB14</scope>
<scope>INTERACTION WITH GRB14</scope>
<scope>AUTOPHOSPHORYLATION</scope>
<scope>PHOSPHORYLATION AT TYR-1185; TYR-1189 AND TYR-1190</scope>
</reference>
<reference key="62">
<citation type="journal article" date="2005" name="Structure" volume="13" first="1643" last="1651">
<title>Crystal structure of a complex between protein tyrosine phosphatase 1B and the insulin receptor tyrosine kinase.</title>
<authorList>
<person name="Li S."/>
<person name="Depetris R.S."/>
<person name="Barford D."/>
<person name="Chernoff J."/>
<person name="Hubbard S.R."/>
</authorList>
<dbReference type="PubMed" id="16271887"/>
<dbReference type="DOI" id="10.1016/j.str.2005.07.019"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH PTPN1</scope>
<scope>PHOSPHORYLATION AT TYR-1185; TYR-1189 AND TYR-1190</scope>
</reference>
<reference key="63">
<citation type="journal article" date="2006" name="Nature" volume="443" first="218" last="221">
<title>Structure of the insulin receptor ectodomain reveals a folded-over conformation.</title>
<authorList>
<person name="McKern N.M."/>
<person name="Lawrence M.C."/>
<person name="Streltsov V.A."/>
<person name="Lou M.Z."/>
<person name="Adams T.E."/>
<person name="Lovrecz G.O."/>
<person name="Elleman T.C."/>
<person name="Richards K.M."/>
<person name="Bentley J.D."/>
<person name="Pilling P.A."/>
<person name="Hoyne P.A."/>
<person name="Cartledge K.A."/>
<person name="Pham T.M."/>
<person name="Lewis J.L."/>
<person name="Sankovich S.E."/>
<person name="Stoichevska V."/>
<person name="Da Silva E."/>
<person name="Robinson C.P."/>
<person name="Frenkel M.J."/>
<person name="Sparrow L.G."/>
<person name="Fernley R.T."/>
<person name="Epa V.C."/>
<person name="Ward C.W."/>
</authorList>
<dbReference type="PubMed" id="16957736"/>
<dbReference type="DOI" id="10.1038/nature05106"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (3.8 ANGSTROMS) OF 28-943 IN COMPLEX WITH INSULIN ANALOG</scope>
<scope>DOMAIN</scope>
<scope>DISULFIDE BONDS</scope>
</reference>
<reference key="64">
<citation type="journal article" date="2006" name="Proc. Natl. Acad. Sci. U.S.A." volume="103" first="12429" last="12434">
<title>The first three domains of the insulin receptor differ structurally from the insulin-like growth factor 1 receptor in the regions governing ligand specificity.</title>
<authorList>
<person name="Lou M."/>
<person name="Garrett T.P."/>
<person name="McKern N.M."/>
<person name="Hoyne P.A."/>
<person name="Epa V.C."/>
<person name="Bentley J.D."/>
<person name="Lovrecz G.O."/>
<person name="Cosgrove L.J."/>
<person name="Frenkel M.J."/>
<person name="Ward C.W."/>
</authorList>
<dbReference type="PubMed" id="16894147"/>
<dbReference type="DOI" id="10.1073/pnas.0605395103"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.32 ANGSTROMS) OF 28-512</scope>
<scope>GLYCOSYLATION AT ASN-43; ASN-52; ASN-138; ASN-242; ASN-282; ASN-364; ASN-424 AND ASN-445</scope>
<scope>DISULFIDE BONDS</scope>
</reference>
<reference key="65">
<citation type="journal article" date="2008" name="Nat. Struct. Mol. Biol." volume="15" first="251" last="258">
<title>Structural and biochemical characterization of the KRLB region in insulin receptor substrate-2.</title>
<authorList>
<person name="Wu J."/>
<person name="Tseng Y.D."/>
<person name="Xu C.F."/>
<person name="Neubert T.A."/>
<person name="White M.F."/>
<person name="Hubbard S.R."/>
</authorList>
<dbReference type="PubMed" id="18278056"/>
<dbReference type="DOI" id="10.1038/nsmb.1388"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH ATP AND IRS2</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>PHOSPHORYLATION AT TYR-1185; TYR-1189 AND TYR-1190</scope>
<scope>INTERACTION WITH IRS2</scope>
</reference>
<reference key="66">
<citation type="journal article" date="2008" name="Proteins" volume="73" first="795" last="801">
<title>Identification of a key element for hydrogen-bonding patterns between protein kinases and their inhibitors.</title>
<authorList>
<person name="Katayama N."/>
<person name="Orita M."/>
<person name="Yamaguchi T."/>
<person name="Hisamichi H."/>
<person name="Kuromitsu S."/>
<person name="Kurihara H."/>
<person name="Sakashita H."/>
<person name="Matsumoto Y."/>
<person name="Fujita S."/>
<person name="Niimi T."/>
</authorList>
<dbReference type="PubMed" id="18767165"/>
<dbReference type="DOI" id="10.1002/prot.22207"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (3.25 ANGSTROMS) OF 1009-1310 IN COMPLEX WITH INHIBITORY PEPTIDE</scope>
<scope>PHOSPHORYLATION AT TYR-1185; TYR-1189 AND TYR-1190</scope>
</reference>
<reference key="67">
<citation type="journal article" date="2009" name="Bioorg. Med. Chem. Lett." volume="19" first="360" last="364">
<title>Optimization of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R tyrosine kinase inhibitors towards JNK selectivity.</title>
<authorList>
<person name="Chamberlain S.D."/>
<person name="Redman A.M."/>
<person name="Wilson J.W."/>
<person name="Deanda F."/>
<person name="Shotwell J.B."/>
<person name="Gerding R."/>
<person name="Lei H."/>
<person name="Yang B."/>
<person name="Stevens K.L."/>
<person name="Hassell A.M."/>
<person name="Shewchuk L.M."/>
<person name="Leesnitzer M.A."/>
<person name="Smith J.L."/>
<person name="Sabbatini P."/>
<person name="Atkins C."/>
<person name="Groy A."/>
<person name="Rowand J.L."/>
<person name="Kumar R."/>
<person name="Mook R.A. Jr."/>
<person name="Moorthy G."/>
<person name="Patnaik S."/>
</authorList>
<dbReference type="PubMed" id="19071018"/>
<dbReference type="DOI" id="10.1016/j.bmcl.2008.11.077"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH SYNTHETIC INHIBITOR</scope>
<scope>CATALYTIC ACTIVITY</scope>
</reference>
<reference key="68">
<citation type="journal article" date="2009" name="Bioorg. Med. Chem. Lett." volume="19" first="469" last="473">
<title>Discovery of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidines: potent inhibitors of the IGF-1R receptor tyrosine kinase.</title>
<authorList>
<person name="Chamberlain S.D."/>
<person name="Wilson J.W."/>
<person name="Deanda F."/>
<person name="Patnaik S."/>
<person name="Redman A.M."/>
<person name="Yang B."/>
<person name="Shewchuk L."/>
<person name="Sabbatini P."/>
<person name="Leesnitzer M.A."/>
<person name="Groy A."/>
<person name="Atkins C."/>
<person name="Gerding R."/>
<person name="Hassell A.M."/>
<person name="Lei H."/>
<person name="Mook R.A. Jr."/>
<person name="Moorthy G."/>
<person name="Rowand J.L."/>
<person name="Stevens K.L."/>
<person name="Kumar R."/>
<person name="Shotwell J.B."/>
</authorList>
<dbReference type="PubMed" id="19056263"/>
<dbReference type="DOI" id="10.1016/j.bmcl.2008.11.046"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH SYNTHETIC INHIBITOR</scope>
<scope>CATALYTIC ACTIVITY</scope>
</reference>
<reference key="69">
<citation type="journal article" date="2009" name="Bioorg. Med. Chem. Lett." volume="19" first="3136" last="3140">
<title>Discovery of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines as potent inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase.</title>
<authorList>
<person name="Patnaik S."/>
<person name="Stevens K.L."/>
<person name="Gerding R."/>
<person name="Deanda F."/>
<person name="Shotwell J.B."/>
<person name="Tang J."/>
<person name="Hamajima T."/>
<person name="Nakamura H."/>
<person name="Leesnitzer M.A."/>
<person name="Hassell A.M."/>
<person name="Shewchuck L.M."/>
<person name="Kumar R."/>
<person name="Lei H."/>
<person name="Chamberlain S.D."/>
</authorList>
<dbReference type="PubMed" id="19394223"/>
<dbReference type="DOI" id="10.1016/j.bmcl.2008.12.110"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 1017-1322 IN COMPLEX WITH SYNTHETIC INHIBITOR</scope>
<scope>CATALYTIC ACTIVITY</scope>
</reference>
<reference key="70">
<citation type="journal article" date="2010" name="Proc. Natl. Acad. Sci. U.S.A." volume="107" first="6771" last="6776">
<title>Structural resolution of a tandem hormone-binding element in the insulin receptor and its implications for design of peptide agonists.</title>
<authorList>
<person name="Smith B.J."/>
<person name="Huang K."/>
<person name="Kong G."/>
<person name="Chan S.J."/>
<person name="Nakagawa S."/>
<person name="Menting J.G."/>
<person name="Hu S.Q."/>
<person name="Whittaker J."/>
<person name="Steiner D.F."/>
<person name="Katsoyannis P.G."/>
<person name="Ward C.W."/>
<person name="Weiss M.A."/>
<person name="Lawrence M.C."/>
</authorList>
<dbReference type="PubMed" id="20348418"/>
<dbReference type="DOI" id="10.1073/pnas.1001813107"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (3.80 ANGSTROMS) OF 28-956</scope>
<scope>INSULIN-BINDING REGION</scope>
<scope>DISULFIDE BONDS</scope>
</reference>
<reference key="71">
<citation type="journal article" date="2013" name="Nature" volume="493" first="241" last="245">
<title>How insulin engages its primary binding site on the insulin receptor.</title>
<authorList>
<person name="Menting J.G."/>
<person name="Whittaker J."/>
<person name="Margetts M.B."/>
<person name="Whittaker L.J."/>
<person name="Kong G.K."/>
<person name="Smith B.J."/>
<person name="Watson C.J."/>
<person name="Zakova L."/>
<person name="Kletvikova E."/>
<person name="Jiracek J."/>
<person name="Chan S.J."/>
<person name="Steiner D.F."/>
<person name="Dodson G.G."/>
<person name="Brzozowski A.M."/>
<person name="Weiss M.A."/>
<person name="Ward C.W."/>
<person name="Lawrence M.C."/>
</authorList>
<dbReference type="PubMed" id="23302862"/>
<dbReference type="DOI" id="10.1038/nature11781"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (3.9 ANGSTROMS) OF 28-620 IN COMPLEX WITH INSULIN</scope>
<scope>DOMAIN</scope>
<scope>GLYCOSYLATION AT ASN-43; ASN-52; ASN-138; ASN-242 AND ASN-282</scope>
<scope>DISULFIDE BONDS</scope>
</reference>
<reference key="72">
<citation type="journal article" date="1988" name="Science" volume="240" first="784" last="787">
<title>Insulin-resistant diabetes due to a point mutation that prevents insulin proreceptor processing.</title>
<authorList>
<person name="Yoshimasa Y."/>
<person name="Seino S."/>
<person name="Whittaker J."/>
<person name="Kakehi T."/>
<person name="Kosaki A."/>
<person name="Kuzuya H."/>
<person name="Imura H."/>
<person name="Bell G.I."/>
<person name="Steiner D.F."/>
</authorList>
<dbReference type="PubMed" id="3283938"/>
<dbReference type="DOI" id="10.1126/science.3283938"/>
</citation>
<scope>VARIANT IRAN TYPE A SER-762</scope>
</reference>
<reference key="73">
<citation type="journal article" date="1988" name="Science" volume="240" first="787" last="790">
<title>Two mutant alleles of the insulin receptor gene in a patient with extreme insulin resistance.</title>
<authorList>
<person name="Kadowaki T."/>
<person name="Bevins C."/>
<person name="Cama A."/>
<person name="Ojamaa K."/>
<person name="Marcus-Samuels B."/>
<person name="Kadowaki H."/>
<person name="Beitz L."/>
<person name="McKeon C."/>
<person name="Taylor S.I."/>
</authorList>
<dbReference type="PubMed" id="2834824"/>
<dbReference type="DOI" id="10.1126/science.2834824"/>
</citation>
<scope>VARIANT LEPRCH GLU-487</scope>
</reference>
<reference key="74">
<citation type="journal article" date="1989" name="EMBO J." volume="8" first="2503" last="2507">
<title>A leucine-to-proline mutation in the insulin receptor in a family with insulin resistance.</title>
<authorList>
<person name="Klinkhamer M.P."/>
<person name="Groen N.A."/>
<person name="van der Zon G.C.M."/>
<person name="Lindhout D."/>
<person name="Sandkuyl L.A."/>
<person name="Krans H.M.J."/>
<person name="Moeller W."/>
<person name="Maassen J.A."/>
</authorList>
<dbReference type="PubMed" id="2479553"/>
</citation>
<scope>VARIANT LEPRCH PRO-260</scope>
</reference>
<reference key="75">
<citation type="journal article" date="1989" name="Science" volume="245" first="66" last="68">
<title>Human diabetes associated with a mutation in the tyrosine kinase domain of the insulin receptor.</title>
<authorList>
<person name="Odawara M."/>
<person name="Kadowaki T."/>
<person name="Yamamoto R."/>
<person name="Shibasaki Y."/>
<person name="Tobe K."/>
<person name="Accili D."/>
<person name="Bevins C."/>
<person name="Mikami Y."/>
<person name="Matsuura N."/>
<person name="Akanuma Y."/>
<person name="Takaku F."/>
<person name="Taylor S.I."/>
<person name="Kasuga M."/>
</authorList>
<dbReference type="PubMed" id="2544998"/>
<dbReference type="DOI" id="10.1126/science.2544998"/>
</citation>
<scope>VARIANT IRAN TYPE A VAL-1035</scope>
</reference>
<reference key="76">
<citation type="journal article" date="1990" name="J. Biol. Chem." volume="265" first="14979" last="14985">
<title>A naturally occurring mutation of insulin receptor alanine 1134 impairs tyrosine kinase function and is associated with dominantly inherited insulin resistance.</title>
<authorList>
<person name="Moller D.E."/>
<person name="Yokota A."/>
<person name="White M.F."/>
<person name="Pazianos A.G."/>
<person name="Flier J.S."/>
</authorList>
<dbReference type="PubMed" id="2168397"/>
</citation>
<scope>VARIANT IRAN TYPE A THR-1161</scope>
</reference>
<reference key="77">
<citation type="journal article" date="1990" name="J. Biol. Chem." volume="265" first="19143" last="19150">
<title>Substitution of lysine for asparagine at position 15 in the alpha-subunit of the human insulin receptor. A mutation that impairs transport of receptors to the cell surface and decreases the affinity of insulin binding.</title>
<authorList>
<person name="Kadowaki T."/>
<person name="Kadowaki H."/>
<person name="Accili D."/>
<person name="Taylor S.I."/>
</authorList>
<dbReference type="PubMed" id="2121734"/>
</citation>
<scope>CHARACTERIZATION OF VARIANT RMS LYS-42</scope>
</reference>
<reference key="78">
<citation type="journal article" date="1990" name="J. Clin. Invest." volume="86" first="254" last="264">
<title>Five mutant alleles of the insulin receptor gene in patients with genetic forms of insulin resistance.</title>
<authorList>
<person name="Kadowaki T."/>
<person name="Kadowaki H."/>
<person name="Rechler M.M."/>
<person name="Serrano-Rios M."/>
<person name="Roth J."/>
<person name="Gorden P."/>
<person name="Taylor S.I."/>
</authorList>
<dbReference type="PubMed" id="2365819"/>
<dbReference type="DOI" id="10.1172/JCI114693"/>
</citation>
<scope>VARIANT RMS LYS-42</scope>
<scope>VARIANT LEPRCH ARG-236</scope>
<scope>VARIANT IRAN TYPE A SER-489</scope>
</reference>
<reference key="79">
<citation type="journal article" date="1990" name="Mol. Endocrinol." volume="4" first="1183" last="1191">
<title>Functional properties of a naturally occurring Trp1200-->Ser1200 mutation of the insulin receptor.</title>
<authorList>
<person name="Moller D.E."/>
<person name="Yokota A."/>
<person name="Ginsberg-Fellner F."/>
<person name="Flier J.S."/>
</authorList>
<dbReference type="PubMed" id="1963473"/>
<dbReference type="DOI" id="10.1210/mend-4-8-1183"/>
</citation>
<scope>VARIANT IRAN TYPE A SER-1227</scope>
</reference>
<reference key="80">
<citation type="journal article" date="1991" name="Diabetes" volume="40" first="777" last="782">
<title>Detection of mutations in insulin-receptor gene in NIDDM patients by analysis of single-stranded conformation polymorphisms.</title>
<authorList>
<person name="O'Rahilly S."/>
<person name="Choi W.H."/>
<person name="Patel P."/>
<person name="Turner R.C."/>
<person name="Flier J.S."/>
<person name="Moller D.E."/>
</authorList>
<dbReference type="PubMed" id="2040394"/>
<dbReference type="DOI" id="10.2337/diab.40.6.777"/>
</citation>
<scope>VARIANT GLU-1095</scope>
</reference>
<reference key="81">
<citation type="journal article" date="1991" name="J. Biol. Chem." volume="266" first="5260" last="5267">
<title>Insulin resistance and diabetes due to different mutations in the tyrosine kinase domain of both insulin receptor gene alleles.</title>
<authorList>
<person name="Kusari J."/>
<person name="Takata Y."/>
<person name="Hatada E."/>
<person name="Freidenberg G."/>
<person name="Kolterman O."/>
<person name="Olefsky J.M."/>
</authorList>
<dbReference type="PubMed" id="2002058"/>
</citation>
<scope>VARIANT IRAN TYPE A GLN-1020</scope>
</reference>
<reference key="82">
<citation type="journal article" date="1991" name="J. Clin. Endocrinol. Metab." volume="73" first="894" last="901">
<title>A mutation in the tyrosine kinase domain of the insulin receptor associated with insulin resistance in an obese woman.</title>
<authorList>
<person name="Cama A."/>
<person name="de la Luz Sierra M."/>
<person name="Ottini L."/>
<person name="Kadowaki T."/>
<person name="Gorden P."/>
<person name="Imperato-Mcginley J."/>
<person name="Taylor S.I."/>
</authorList>
<dbReference type="PubMed" id="1890161"/>
<dbReference type="DOI" id="10.1210/jcem-73-4-894"/>
</citation>
<scope>VARIANT INS RESISTANCE ILE-1180</scope>
</reference>
<reference key="83">
<citation type="journal article" date="1992" name="Diabetes" volume="41" first="408" last="415">
<title>Detection of mutations in insulin receptor gene by denaturing gradient gel electrophoresis.</title>
<authorList>
<person name="Barbetti F."/>
<person name="Gejman P.V."/>
<person name="Taylor S.I."/>
<person name="Raben N."/>
<person name="Cama A."/>
<person name="Bonora E."/>
<person name="Pizzo P."/>
<person name="Moghetti P."/>
<person name="Muggeo M."/>
<person name="Roth J."/>
</authorList>
<dbReference type="PubMed" id="1607067"/>
<dbReference type="DOI" id="10.2337/diab.41.4.408"/>
</citation>
<scope>VARIANTS LEPRCH ALA-55 AND ARG-393</scope>
</reference>
<reference key="84">
<citation type="journal article" date="1992" name="Diabetes" volume="41" first="521" last="526">
<title>NIDDM associated with mutation in tyrosine kinase domain of insulin receptor gene.</title>
<authorList>
<person name="Cocozza S."/>
<person name="Porcellini A."/>
<person name="Riccardi G."/>
<person name="Monticelli A."/>
<person name="Condorelli G."/>
<person name="Ferrara A."/>
<person name="Pianese L."/>
<person name="Miele C."/>
<person name="Capaldo B."/>
<person name="Beguinot F."/>
<person name="Varrone S."/>
</authorList>
<dbReference type="PubMed" id="1607076"/>
<dbReference type="DOI" id="10.2337/diab.41.4.521"/>
</citation>
<scope>VARIANT NIDDM GLN-1191</scope>
</reference>
<reference key="85">
<citation type="journal article" date="1992" name="Diabetologia" volume="35" first="261" last="266">
<title>Detection of mutations in the insulin receptor gene in patients with insulin resistance by analysis of single-stranded conformational polymorphisms.</title>
<authorList>
<person name="Kim H."/>
<person name="Kadowaki H."/>
<person name="Sakura H."/>
<person name="Odawara M."/>
<person name="Momomura K."/>
<person name="Takahashi Y."/>
<person name="Miyazaki Y."/>
<person name="Ohtani T."/>
<person name="Akanuma Y."/>
<person name="Yazaki Y."/>
<person name="Kasuga M."/>
<person name="Taylor S.I."/>
<person name="Kadowaki T."/>
</authorList>
<dbReference type="PubMed" id="1563582"/>
<dbReference type="DOI" id="10.1007/BF00400927"/>
</citation>
<scope>VARIANT IRAN TYPE A LEU-1205</scope>
</reference>
<reference key="86">
<citation type="journal article" date="1992" name="J. Biol. Chem." volume="267" first="66" last="71">
<title>An Arg for Gly substitution at position 31 in the insulin receptor, linked to insulin resistance, inhibits receptor processing and transport.</title>
<authorList>
<person name="van der Vorm E.R."/>
<person name="van der Zon G.C.M."/>
<person name="Moeller W."/>
<person name="Krans H.M.J."/>
<person name="Lindhout D."/>
<person name="Maassen J.A."/>
</authorList>
<dbReference type="PubMed" id="1730625"/>
</citation>
<scope>VARIANT LEPRCH ARG-58</scope>
</reference>
<reference key="87">
<citation type="journal article" date="1992" name="Nihon Geka Gakkai Zasshi" volume="93" first="968" last="971">
<title>Insulin receptor Arg1131-->Gln: a novel mutation in the catalytic loop of insulin receptor observed in insulin resistant diabetes.</title>
<authorList>
<person name="Kasuga M."/>
<person name="Kishimoto M."/>
<person name="Hashiramoto M."/>
<person name="Yonezawa K."/>
<person name="Kazumi T."/>
<person name="Hagino H."/>
<person name="Shii K."/>
</authorList>
<dbReference type="PubMed" id="1470163"/>
</citation>
<scope>VARIANT NIDDM GLN-1158</scope>
</reference>
<reference key="88">
<citation type="journal article" date="1993" name="Diabetes" volume="42" first="429" last="434">
<title>Methionine for valine substitution in exon 17 of the insulin receptor gene in a pedigree with familial NIDDM.</title>
<authorList>
<person name="Elbein S.C."/>
<person name="Sorensen L.K."/>
<person name="Schumacher M.C."/>
</authorList>
<dbReference type="PubMed" id="8432414"/>
<dbReference type="DOI" id="10.2337/diab.42.3.429"/>
</citation>
<scope>VARIANT MET-1012</scope>
</reference>
<reference key="89">
<citation type="journal article" date="1993" name="Diabetes" volume="42" first="1837" last="1844">
<title>Ala1048-->Asp mutation in the kinase domain of insulin receptor causes defective kinase activity and insulin resistance.</title>
<authorList>
<person name="Haruta T."/>
<person name="Takata Y."/>
<person name="Iwanishi M."/>
<person name="Maegawa H."/>
<person name="Imamura T."/>
<person name="Egawa K."/>
<person name="Itazu T."/>
<person name="Kobayashi M."/>
</authorList>
<dbReference type="PubMed" id="8243830"/>
<dbReference type="DOI" id="10.2337/diab.42.12.1837"/>
</citation>
<scope>VARIANT IRAN TYPE A ASP-1075</scope>
</reference>
<reference key="90">
<citation type="journal article" date="1993" name="Diabetologia" volume="36" first="172" last="174">
<title>Patients with lipodystrophic diabetes mellitus of the Seip-Berardinelli type, express normal insulin receptors.</title>
<authorList>
<person name="van der Vorm E.R."/>
<person name="Kuipers A."/>
<person name="Bonenkamp J.W."/>
<person name="Kleijer W.J."/>
<person name="van Maldergem L."/>
<person name="Herwig J."/>
<person name="Maassen J.A."/>
</authorList>
<dbReference type="PubMed" id="8458533"/>
<dbReference type="DOI" id="10.1007/BF00400701"/>
</citation>
<scope>VARIANT MET-1012</scope>
</reference>
<reference key="91">
<citation type="journal article" date="1993" name="Diabetologia" volume="36" first="414" last="422">
<title>A mutation (Trp1193-->Leu1193) in the tyrosine kinase domain of the insulin receptor associated with type A syndrome of insulin resistance.</title>
<authorList>
<person name="Iwanishi M."/>
<person name="Haruta T."/>
<person name="Takata Y."/>
<person name="Ishibashi O."/>
<person name="Sasaoka T."/>
<person name="Egawa K."/>
<person name="Imamura T."/>
<person name="Naitou K."/>
<person name="Itazu T."/>
<person name="Kobayashi M."/>
</authorList>
<dbReference type="PubMed" id="8390949"/>
<dbReference type="DOI" id="10.1007/BF00402277"/>
</citation>
<scope>VARIANT INS RESISTANCE LEU-1220</scope>
</reference>
<reference key="92">
<citation type="journal article" date="1993" name="Hum. Mol. Genet." volume="2" first="1437" last="1441">
<title>Substitution of Leu for Pro-193 in the insulin receptor in a patient with a genetic form of severe insulin resistance.</title>
<authorList>
<person name="Carrera P."/>
<person name="Cordera R."/>
<person name="Ferrari M."/>
<person name="Cremonesi L."/>
<person name="Taramelli R."/>
<person name="Andraghetti G."/>
<person name="Carducci C."/>
<person name="Dozio N."/>
<person name="Pozza G."/>
<person name="Taylor S.I."/>
<person name="Micossi P."/>
<person name="Barbetti F."/>
</authorList>
<dbReference type="PubMed" id="8242067"/>
<dbReference type="DOI" id="10.1093/hmg/2.9.1437"/>
</citation>
<scope>VARIANT INS RESISTANCE LEU-220</scope>
</reference>
<reference key="93">
<citation type="journal article" date="1993" name="J. Biol. Chem." volume="268" first="8060" last="8069">
<title>Substitution of glutamic acid for alanine 1135 in the putative 'catalytic loop' of the tyrosine kinase domain of the human insulin receptor. A mutation that impairs proteolytic processing into subunits and inhibits receptor tyrosine kinase activity.</title>
<authorList>
<person name="Cama A."/>
<person name="de la Luz Sierra M."/>
<person name="Quon M.J."/>
<person name="Ottini L."/>
<person name="Gorden P."/>
<person name="Taylor S.I."/>
</authorList>
<dbReference type="PubMed" id="8096518"/>
</citation>
<scope>CHARACTERIZATION OF VARIANT IRAN TYPE A GLU-1162</scope>
</reference>
<reference key="94">
<citation type="journal article" date="1993" name="J. Biol. Chem." volume="268" first="11272" last="11277">
<title>Antibodies to the extracellular receptor domain restore the hormone-insensitive kinase and conformation of the mutant insulin receptor valine 382.</title>
<authorList>
<person name="Lebrun C."/>
<person name="Baron V."/>
<person name="Kaliman P."/>
<person name="Gautier N."/>
<person name="Dolais-Kitabgi J."/>
<person name="Taylor S.I."/>
<person name="Accili D."/>
<person name="van Obberghen E."/>
</authorList>
<dbReference type="PubMed" id="8388389"/>
</citation>
<scope>VARIANT IRAN TYPE A VAL-409</scope>
</reference>
<reference key="95">
<citation type="journal article" date="1993" name="J. Med. Genet." volume="30" first="470" last="475">
<title>A syndrome of insulin resistance resembling leprechaunism in five sibs of consanguineous parents.</title>
<authorList>
<person name="Al-Gazali L.I."/>
<person name="Khalil M."/>
<person name="Devadas K."/>
</authorList>
<dbReference type="PubMed" id="8326490"/>
<dbReference type="DOI" id="10.1136/jmg.30.6.470"/>
</citation>
<scope>VARIANT LEPRCH MET-146</scope>
</reference>
<reference key="96">
<citation type="journal article" date="1993" name="Proc. Natl. Acad. Sci. U.S.A." volume="90" first="60" last="64">
<title>Activation of glucose transport by a natural mutation in the human insulin receptor.</title>
<authorList>
<person name="Longo N."/>
<person name="Langley S.D."/>
<person name="Griffin L.D."/>
<person name="Elsas L.J."/>
</authorList>
<dbReference type="PubMed" id="8419945"/>
<dbReference type="DOI" id="10.1073/pnas.90.1.60"/>
</citation>
<scope>VARIANT LEPRCH PRO-113</scope>
</reference>
<reference key="97">
<citation type="journal article" date="1994" name="Diabetes" volume="43" first="247" last="255">
<title>Prevalence of mutations in the insulin receptor gene in subjects with features of the type A syndrome of insulin resistance.</title>
<authorList>
<person name="Moller D.E."/>
<person name="Cohen O."/>
<person name="Yamaguchi Y."/>
<person name="Assiz R."/>
<person name="Grigorescu F."/>
<person name="Eberle A."/>
<person name="Morrow L.A."/>
<person name="Moses A.C."/>
<person name="Flier J.S."/>
</authorList>
<dbReference type="PubMed" id="8288049"/>
<dbReference type="DOI" id="10.2337/diab.43.2.247"/>
</citation>
<scope>VARIANT IRAN TYPE A GLN-1201</scope>
</reference>
<reference key="98">
<citation type="journal article" date="1994" name="Diabetes" volume="43" first="357" last="368">
<title>Molecular scanning of the insulin receptor gene in syndromes of insulin resistance.</title>
<authorList>
<person name="Krook A."/>
<person name="Kumar S."/>
<person name="Laing I."/>
<person name="Boulton A.J."/>
<person name="Wass J.A."/>
<person name="O'Rahilly S."/>
</authorList>
<dbReference type="PubMed" id="8314008"/>
<dbReference type="DOI" id="10.2337/diab.43.3.357"/>
</citation>
<scope>VARIANT RMS SYNDROME LEU-350</scope>
<scope>VARIANTS IRAN TYPE A LEU-1205 AND GLN-1378</scope>
<scope>VARIANT MET-1012</scope>
</reference>
<reference key="99">
<citation type="journal article" date="1994" name="FEBS Lett." volume="351" first="276" last="280">
<title>Functional properties of a heterozygous mutation (Arg1174-->Gln) in the tyrosine kinase domain of the insulin receptor from a type A insulin resistant patient.</title>
<authorList>
<person name="Moritz W."/>
<person name="Froesch E.R."/>
<person name="Boeni-Schnetzler M."/>
</authorList>
<dbReference type="PubMed" id="8082780"/>
<dbReference type="DOI" id="10.1016/0014-5793(94)00876-0"/>
</citation>
<scope>CHARACTERIZATION OF VARIANT IRAN TYPE A GLN-1201</scope>
</reference>
<reference key="100">
<citation type="journal article" date="1994" name="J. Biol. Chem." volume="269" first="14297" last="14302">
<title>A mutation in the insulin receptor that impairs proreceptor processing but not insulin binding.</title>
<authorList>
<person name="van der Vorm E.R."/>
<person name="Kuipers A."/>
<person name="Kielkopf-Renner S."/>
<person name="Krans H.M.J."/>
<person name="Moller W."/>
<person name="Maassen J.A."/>
</authorList>
<dbReference type="PubMed" id="8188715"/>
</citation>
<scope>VARIANT LEPRCH SER-439</scope>
</reference>
<reference key="101">
<citation type="journal article" date="1994" name="J. Biol. Chem." volume="269" first="31019" last="31027">
<title>Two naturally occurring mutations in the kinase domain of insulin receptor accelerate degradation of the insulin receptor and impair the kinase activity.</title>
<authorList>
<person name="Imamura T."/>
<person name="Takata Y."/>
<person name="Sasaoka T."/>
<person name="Takada Y."/>
<person name="Morioka H."/>
<person name="Haruta T."/>
<person name="Sawa T."/>
<person name="Iwanishi M."/>
<person name="Hu Y.G."/>
<person name="Suzuki Y."/>
<person name="Hamada J."/>
<person name="Kobayashi M."/>
</authorList>
<dbReference type="PubMed" id="7983039"/>
</citation>
<scope>CHARACTERIZATION OF VARIANTS IRAN TYPE A ASP-1206 AND LEU-1220</scope>
</reference>
<reference key="102">
<citation type="journal article" date="1994" name="J. Med. Genet." volume="31" first="715" last="716">
<title>Homozygosity for a new mutation (Ile119-->Met) in the insulin receptor gene in five sibs with familial insulin resistance.</title>
<authorList>
<person name="Hone J."/>
<person name="Accili D."/>
<person name="al-Gazali L.I."/>
<person name="Lestringant G."/>
<person name="Orban T."/>
<person name="Taylor S.I."/>
</authorList>
<dbReference type="PubMed" id="7815442"/>
<dbReference type="DOI" id="10.1136/jmg.31.9.715"/>
</citation>
<scope>VARIANT LEPRCH MET-146</scope>
</reference>
<reference key="103">
<citation type="journal article" date="1995" name="Diabetes" volume="44" first="1081" last="1086">
<title>Frequency of mutations of insulin receptor gene in Japanese patients with NIDDM.</title>
<authorList>
<person name="Kan M."/>
<person name="Kanai F."/>
<person name="Iida M."/>
<person name="Jinnouchi H."/>
<person name="Todaka M."/>
<person name="Imanaka T."/>
<person name="Ito K."/>
<person name="Nishioka Y."/>
<person name="Ohnishi T."/>
<person name="Kamohara S."/>
<person name="Hayashi H."/>
<person name="Murakami T."/>
<person name="Kagawa S."/>
<person name="Sano H."/>
<person name="Hashimoto N."/>
<person name="Yoshida S."/>
<person name="Makino H."/>
<person name="Ebina Y."/>
</authorList>
<dbReference type="PubMed" id="7657032"/>
<dbReference type="DOI" id="10.2337/diab.44.9.1081"/>
</citation>
<scope>VARIANT NIDDM ALA-858</scope>
<scope>VARIANT CYS-1361</scope>
</reference>
<reference key="104">
<citation type="journal article" date="1995" name="J. Clin. Endocrinol. Metab." volume="80" first="1496" last="1501">
<title>Two mutations in the insulin receptor gene of a patient with leprechaunism: application to prenatal diagnosis.</title>
<authorList>
<person name="Longo N."/>
<person name="Langley S.D."/>
<person name="Griffin L.D."/>
<person name="Elsas L.J."/>
</authorList>
<dbReference type="PubMed" id="7538143"/>
<dbReference type="DOI" id="10.1210/jcem.80.5.7538143"/>
</citation>
<scope>VARIANT LEPRCH ASN-308 DEL</scope>
</reference>
<reference key="105">
<citation type="journal article" date="1996" name="Eur. J. Endocrinol." volume="135" first="357" last="363">
<title>In-frame exon 2 deletion in insulin receptor RNA in a family with extreme insulin resistance in association with defective insulin binding: a case report.</title>
<authorList>
<person name="Moritz W."/>
<person name="Boeni-Schnetzler M."/>
<person name="Stevens W."/>
<person name="Froesch E.R."/>
<person name="Levy J.R."/>
</authorList>
<dbReference type="PubMed" id="8890729"/>
<dbReference type="DOI" id="10.1530/eje.0.1350357"/>
</citation>
<scope>VARIANT PHE-1023</scope>
</reference>
<reference key="106">
<citation type="journal article" date="1996" name="J. Clin. Endocrinol. Metab." volume="81" first="719" last="727">
<title>Deletion of Asn281 in the alpha-subunit of the human insulin receptor causes constitutive activation of the receptor and insulin desensitization.</title>
<authorList>
<person name="Desbois-Mouthon C."/>
<person name="Sert-Langeron C."/>
<person name="Magre J."/>
<person name="Oreal E."/>
<person name="Blivet M.J."/>
<person name="Flori E."/>
<person name="Besmond C."/>
<person name="Capeau J."/>
<person name="Caron M."/>
</authorList>
<dbReference type="PubMed" id="8636294"/>
<dbReference type="DOI" id="10.1210/jcem.81.2.8636294"/>
</citation>
<scope>VARIANT LEPRCH ASN-308 DEL</scope>
</reference>
<reference key="107">
<citation type="journal article" date="1997" name="Am. J. Hum. Genet." volume="60" first="1532" last="1535">
<title>The Val985Met insulin-receptor variant in the Danish Caucasian population: lack of associations with non-insulin-dependent diabetes mellitus or insulin resistance.</title>
<authorList>
<person name="Hansen L."/>
<person name="Hansen T."/>
<person name="Clausen J.O."/>
<person name="Echwald S.M."/>
<person name="Urhammer S.A."/>
<person name="Rasmussen S.K."/>
<person name="Pedersen O."/>
</authorList>
<dbReference type="PubMed" id="9199575"/>
<dbReference type="DOI" id="10.1086/515464"/>
</citation>
<scope>VARIANT MET-1012</scope>
</reference>
<reference key="108">
<citation type="journal article" date="1997" name="Biochem. Biophys. Res. Commun." volume="234" first="764" last="768">
<title>Identification of two novel insulin receptor mutations, Asp59Gly and Leu62Pro, in type A syndrome of extreme insulin resistance.</title>
<authorList>
<person name="Rouard M."/>
<person name="Macari F."/>
<person name="Bouix O."/>
<person name="Lautier C."/>
<person name="Brun J.F."/>
<person name="Lefebvre P."/>
<person name="Renard E."/>
<person name="Bringer J."/>
<person name="Jaffiol C."/>
<person name="Grigorescu F."/>
</authorList>
<dbReference type="PubMed" id="9175790"/>
<dbReference type="DOI" id="10.1006/bbrc.1997.6695"/>
</citation>
<scope>VARIANTS IRAN TYPE A GLY-86 AND PRO-89</scope>
</reference>
<reference key="109">
<citation type="journal article" date="1997" name="Biochem. Biophys. Res. Commun." volume="237" first="516" last="520">
<title>Four mutant alleles of the insulin receptor gene associated with genetic syndromes of extreme insulin resistance.</title>
<authorList>
<person name="Kadowaki H."/>
<person name="Takahashi Y."/>
<person name="Ando A."/>
<person name="Momomura K."/>
<person name="Kaburagi Y."/>
<person name="Quin J.D."/>
<person name="MacCuish A.C."/>
<person name="Koda N."/>
<person name="Fukushima Y."/>
<person name="Taylor S.I."/>
<person name="Akanuma Y."/>
<person name="Yazaki Y."/>
<person name="Kadowaki T."/>
</authorList>
<dbReference type="PubMed" id="9299395"/>
<dbReference type="DOI" id="10.1006/bbrc.1997.7181"/>
</citation>
<scope>CHARACTERIZATION OF VARIANT LEPRCH MET-937</scope>
</reference>
<reference key="110">
<citation type="journal article" date="1997" name="Prenat. Diagn." volume="17" first="657" last="663">
<title>Molecular analysis of the insulin receptor gene for prenatal diagnosis of leprechaunism in two families.</title>
<authorList>
<person name="Desbois-Mouthon C."/>
<person name="Girodon E."/>
<person name="Ghanem N."/>
<person name="Caron M."/>
<person name="Pennerath A."/>
<person name="Conteville P."/>
<person name="Magre J."/>
<person name="Besmond C."/>
<person name="Goossens M."/>
<person name="Capeau J."/>
<person name="Amselem S."/>
</authorList>
<dbReference type="PubMed" id="9249867"/>
<dbReference type="DOI" id="10.1002/(SICI)1097-0223(199707)17:7&lt;657::AID-PD132>3.3.CO;2-#"/>
</citation>
<scope>VARIANTS LEPRCH TRP-1119 AND LYS-1206</scope>
</reference>
<reference key="111">
<citation type="journal article" date="1998" name="Diabetes" volume="47" first="1362" last="1364">
<title>Multiple molecular mechanisms of insulin receptor dysfunction in a patient with Donohue syndrome.</title>
<authorList>
<person name="Whitehead J.P."/>
<person name="Soos M.A."/>
<person name="Jackson R."/>
<person name="Tasic V."/>
<person name="Kocova M."/>
<person name="O'Rahilly S."/>
</authorList>
<dbReference type="PubMed" id="9703342"/>
<dbReference type="DOI" id="10.2337/diab.47.8.1362"/>
</citation>
<scope>VARIANTS LEPRCH TYR-301 AND TRP-1201</scope>
</reference>
<reference key="112">
<citation type="journal article" date="1999" name="J. Clin. Endocrinol. Metab." volume="84" first="2623" last="2629">
<title>Progressive decline in insulin levels in Rabson-Mendenhall syndrome.</title>
<authorList>
<person name="Longo N."/>
<person name="Wang Y."/>
<person name="Pasquali M."/>
</authorList>
<dbReference type="PubMed" id="10443650"/>
<dbReference type="DOI" id="10.1210/jcem.84.8.5902"/>
</citation>
<scope>VARIANTS RMS THR-1143 AND TRP-1158</scope>
</reference>
<reference key="113">
<citation type="journal article" date="2000" name="Clin. Genet." volume="57" first="67" last="69">
<title>Identification of three novel mutations in the insulin receptor gene in type A insulin resistant patients.</title>
<authorList>
<person name="Rique S."/>
<person name="Nogues C."/>
<person name="Ibanez L."/>
<person name="Marcos M.V."/>
<person name="Ferragut J."/>
<person name="Carrascosa A."/>
<person name="Potau N."/>
</authorList>
<dbReference type="PubMed" id="10733238"/>
<dbReference type="DOI" id="10.1034/j.1399-0004.2000.570110.x"/>
</citation>
<scope>VARIANTS IRAN TYPE A LEU-167 AND VAL-1055</scope>
</reference>
<reference key="114">
<citation type="journal article" date="2001" name="Clin. Genet." volume="59" first="194" last="197">
<title>Identification of novel C253Y missense and Y864X nonsense mutations in the insulin receptor gene in type A insulin-resistant patients.</title>
<authorList>
<person name="Osawa H."/>
<person name="Nishimiya T."/>
<person name="Ochi M."/>
<person name="Niiya T."/>
<person name="Onuma H."/>
<person name="Kitamuro F."/>
<person name="Kaino Y."/>
<person name="Kida K."/>
<person name="Makino H."/>
</authorList>
<dbReference type="PubMed" id="11260230"/>
<dbReference type="DOI" id="10.1034/j.1399-0004.2001.590309.x"/>
</citation>
<scope>VARIANT IRAN TYPE A TYR-280</scope>
</reference>
<reference key="115">
<citation type="journal article" date="2002" name="Diabetologia" volume="45" first="657" last="667">
<title>An arginine to cysteine(252) mutation in insulin receptors from a patient with severe insulin resistance inhibits receptor internalisation but preserves signalling events.</title>
<authorList>
<person name="Hamer I."/>
<person name="Foti M."/>
<person name="Emkey R."/>
<person name="Cordier-Bussat M."/>
<person name="Philippe J."/>
<person name="De Meyts P."/>
<person name="Maeder C."/>
<person name="Kahn C.R."/>
<person name="Carpentier J.-L."/>
</authorList>
<dbReference type="PubMed" id="12107746"/>
<dbReference type="DOI" id="10.1007/s00125-002-0798-5"/>
</citation>
<scope>VARIANT IRAN TYPE A CYS-279</scope>
</reference>
<reference key="116">
<citation type="journal article" date="2002" name="Hum. Mol. Genet." volume="11" first="1465" last="1475">
<title>Genotype-phenotype correlation in inherited severe insulin resistance.</title>
<authorList>
<person name="Longo N."/>
<person name="Wang Y."/>
<person name="Smith S.A."/>
<person name="Langley S.D."/>
<person name="DiMeglio L.A."/>
<person name="Giannella-Neto D."/>
</authorList>
<dbReference type="PubMed" id="12023989"/>
<dbReference type="DOI" id="10.1093/hmg/11.12.1465"/>
</citation>
<scope>CHARACTERIZATION OF VARIANTS LEPRCH PRO-113; VAL-119; ASN-308 DEL; THR-925 AND TRP-926</scope>
<scope>VARIANTS RMS THR-997; THR-1143; TRP-1158 AND TRP-1201</scope>
</reference>
<reference key="117">
<citation type="journal article" date="2003" name="Endocrinology" volume="144" first="631" last="637">
<title>Deletion of V335 from the L2 domain of the insulin receptor results in a conformationally abnormal receptor that is unable to bind insulin and causes Donohue's syndrome in a human subject.</title>
<authorList>
<person name="George S."/>
<person name="Johansen A."/>
<person name="Soos M.A."/>
<person name="Mortensen H."/>
<person name="Gammeltoft S."/>
<person name="Saudek V."/>
<person name="Siddle K."/>
<person name="Hansen L."/>
<person name="O'Rahilly S."/>
</authorList>
<dbReference type="PubMed" id="12538626"/>
<dbReference type="DOI" id="10.1210/en.2002-220815"/>
</citation>
<scope>VARIANT LEPRCH VAL-362 DEL</scope>
</reference>
<reference key="118">
<citation type="journal article" date="2003" name="J. Clin. Endocrinol. Metab." volume="88" first="4251" last="4257">
<title>Identification and functional assessment of novel and known insulin receptor mutations in five patients with syndromes of severe insulin resistance.</title>
<authorList>
<person name="Maassen J.A."/>
<person name="Tobias E.S."/>
<person name="Kayserilli H."/>
<person name="Tukel T."/>
<person name="Yuksel-Apak M."/>
<person name="D'Haens E."/>
<person name="Kleijer W.J."/>
<person name="Fery F."/>
<person name="van der Zon G.C.M."/>
</authorList>
<dbReference type="PubMed" id="12970295"/>
<dbReference type="DOI" id="10.1210/jc.2003-030034"/>
</citation>
<scope>VARIANT IRAN TYPE A HIS-279</scope>
<scope>VARIANTS LEPRCH GLN-120; LEU-350; ASP-458 AND TRP-1119</scope>
<scope>CHARACTERIZATION OF VARIANT IRAN TYPE A HIS-279</scope>
<scope>CHARACTERIZATION OF VARIANTS LEPRCH GLN-120 AND ASP-458</scope>
</reference>
<reference key="119">
<citation type="journal article" date="2004" name="Diabetes" volume="53" first="1592" last="1598">
<title>A novel syndrome of autosomal-dominant hyperinsulinemic hypoglycemia linked to a mutation in the human insulin receptor gene.</title>
<authorList>
<person name="Hoejlund K."/>
<person name="Hansen T."/>
<person name="Lajer M."/>
<person name="Henriksen J.E."/>
<person name="Levin K."/>
<person name="Lindholm J."/>
<person name="Pedersen O."/>
<person name="Bech-Nielsen H."/>
</authorList>
<dbReference type="PubMed" id="15161766"/>
<dbReference type="DOI" id="10.2337/diabetes.53.6.1592"/>
</citation>
<scope>VARIANT HHF5 GLN-1201</scope>
</reference>
<reference key="120">
<citation type="journal article" date="2007" name="Clin. Endocrinol. (Oxf.)" volume="66" first="21" last="26">
<title>Functional characterization of a novel insulin receptor mutation contributing to Rabson-Mendenhall syndrome.</title>
<authorList>
<person name="Tuthill A."/>
<person name="Semple R.K."/>
<person name="Day R."/>
<person name="Soos M.A."/>
<person name="Sweeney E."/>
<person name="Seymour P.J."/>
<person name="Didi M."/>
<person name="O'Rahilly S."/>
</authorList>
<dbReference type="PubMed" id="17201797"/>
<dbReference type="DOI" id="10.1111/j.1365-2265.2006.02678.x"/>
</citation>
<scope>VARIANTS RMS ARG-236 AND SER-386</scope>
<scope>CHARACTERIZATION OF VARIANTS RMS ARG-236 AND SER-386</scope>
</reference>
<reference key="121">
<citation type="journal article" date="2007" name="Nature" volume="446" first="153" last="158">
<title>Patterns of somatic mutation in human cancer genomes.</title>
<authorList>
<person name="Greenman C."/>
<person name="Stephens P."/>
<person name="Smith R."/>
<person name="Dalgliesh G.L."/>
<person name="Hunter C."/>
<person name="Bignell G."/>
<person name="Davies H."/>
<person name="Teague J."/>
<person name="Butler A."/>
<person name="Stevens C."/>
<person name="Edkins S."/>
<person name="O'Meara S."/>
<person name="Vastrik I."/>
<person name="Schmidt E.E."/>
<person name="Avis T."/>
<person name="Barthorpe S."/>
<person name="Bhamra G."/>
<person name="Buck G."/>
<person name="Choudhury B."/>
<person name="Clements J."/>
<person name="Cole J."/>
<person name="Dicks E."/>
<person name="Forbes S."/>
<person name="Gray K."/>
<person name="Halliday K."/>
<person name="Harrison R."/>
<person name="Hills K."/>
<person name="Hinton J."/>
<person name="Jenkinson A."/>
<person name="Jones D."/>
<person name="Menzies A."/>
<person name="Mironenko T."/>
<person name="Perry J."/>
<person name="Raine K."/>
<person name="Richardson D."/>
<person name="Shepherd R."/>
<person name="Small A."/>
<person name="Tofts C."/>
<person name="Varian J."/>
<person name="Webb T."/>
<person name="West S."/>
<person name="Widaa S."/>
<person name="Yates A."/>
<person name="Cahill D.P."/>
<person name="Louis D.N."/>
<person name="Goldstraw P."/>
<person name="Nicholson A.G."/>
<person name="Brasseur F."/>
<person name="Looijenga L."/>
<person name="Weber B.L."/>
<person name="Chiew Y.-E."/>
<person name="DeFazio A."/>
<person name="Greaves M.F."/>
<person name="Green A.R."/>
<person name="Campbell P."/>
<person name="Birney E."/>
<person name="Easton D.F."/>
<person name="Chenevix-Trench G."/>
<person name="Tan M.-H."/>
<person name="Khoo S.K."/>
<person name="Teh B.T."/>
<person name="Yuen S.T."/>
<person name="Leung S.Y."/>
<person name="Wooster R."/>
<person name="Futreal P.A."/>
<person name="Stratton M.R."/>
</authorList>
<dbReference type="PubMed" id="17344846"/>
<dbReference type="DOI" id="10.1038/nature05610"/>
</citation>
<scope>VARIANTS [LARGE SCALE ANALYSIS] ARG-228; ARG-695; SER-811; MET-1012; VAL-1065 AND ALA-1282</scope>
</reference>
<comment type="function">
<text evidence="33 50 51 101 102 110 123">Receptor tyrosine kinase which mediates the pleiotropic actions of insulin. Binding of insulin leads to phosphorylation of several intracellular substrates, including, insulin receptor substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling intermediates. Each of these phosphorylated proteins serve as docking proteins for other signaling proteins that contain Src-homology-2 domains (SH2 domain) that specifically recognize different phosphotyrosine residues, including the p85 regulatory subunit of PI3K and SHP2. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway, which is responsible for most of the metabolic actions of insulin, and the Ras-MAPK pathway, which regulates expression of some genes and cooperates with the PI3K pathway to control cell growth and differentiation. Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to the activation of PI3K and the generation of phosphatidylinositol-(3, 4, 5)-triphosphate (PIP3), a lipid second messenger, which activates several PIP3-dependent serine/threonine kinases, such as PDPK1 and subsequently AKT/PKB. The net effect of this pathway is to produce a translocation of the glucose transporter SLC2A4/GLUT4 from cytoplasmic vesicles to the cell membrane to facilitate glucose transport. Moreover, upon insulin stimulation, activated AKT/PKB is responsible for: anti-apoptotic effect of insulin by inducing phosphorylation of BAD; regulates the expression of gluconeogenic and lipogenic enzymes by controlling the activity of the winged helix or forkhead (FOX) class of transcription factors. Another pathway regulated by PI3K-AKT/PKB activation is mTORC1 signaling pathway which regulates cell growth and metabolism and integrates signals from insulin. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 thereby activating mTORC1 pathway. The Ras/RAF/MAP2K/MAPK pathway is mainly involved in mediating cell growth, survival and cellular differentiation of insulin. Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers the activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to binding insulin, the insulin receptor can bind insulin-like growth factors (IGFI and IGFII). Isoform Short has a higher affinity for IGFII binding. When present in a hybrid receptor with IGF1R, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.</text>
</comment>
<comment type="catalytic activity">
<text evidence="19 26 29 37 57 60 61 64 121">ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.</text>
</comment>
<comment type="enzyme regulation">
<text evidence="22 29 30 34 72">Activated in response to insulin. Autophosphorylation activates the kinase activity. PTPN1, PTPRE and PTPRF dephosphorylate important tyrosine residues, thereby reducing INSR activity. Inhibited by ENPP1. GRB10 and GRB14 inhibit the catalytic activity of the INSR, they block access of substrates to the activated receptor. SOCS1 and SOCS3 act as negative regulators of INSR activity, they bind to the activated INRS and interfere with the phosphorylation of INSR substrates.</text>
</comment>
<comment type="subunit">
<text evidence="14 15 22 25 26 28 30 34 39 47 48 49 50 53 57 58 60 61 64 72 74 79 90 92 102 114 115 121 123">Tetramer of 2 alpha and 2 beta chains linked by disulfide bonds. The alpha chains carry the insulin-binding regions, while the beta chains carry the kinase domain. Forms a hybrid receptor with IGF1R, the hybrid is a tetramer consisting of 1 alpha chain and 1 beta chain of INSR and 1 alpha chain and 1 beta chain of IGF1R. Interacts with SORBS1 but dissociates from it following insulin stimulation. Binds SH2B2. Activated form of INSR interacts (via Tyr-999) with the PTB/PID domains of IRS1 and SHC1. The sequences surrounding the phosphorylated NPXY motif contribute differentially to either IRS1 or SHC1 recognition. Interacts (via tyrosines in the C-terminus) with IRS2 (via PTB domain and 591-786 AA); the 591-786 would be the primary anchor of IRS2 to INSR while the PTB domain would have a stabilizing action on the interaction with INSR. Interacts with the SH2 domains of the 85 kDa regulatory subunit of PI3K (PIK3R1) in vitro, when autophosphorylated on tyrosine residues. Interacts with SOCS7. Interacts (via the phosphorylated Tyr-999), with SOCS3. Interacts (via the phosphorylated Tyr-1185, Tyr-1189, Tyr-1190) with SOCS1. Interacts with CAV2 (tyrosine-phosphorylated form); the interaction is increased with 'Tyr-27'phosphorylation of CAV2 (By similarity). Interacts with ARRB2 (By similarity). Interacts with GRB10; this interaction blocks the association between IRS1/IRS2 and INSR, significantly reduces insulin-stimulated tyrosine phosphorylation of IRS1 and IRS2 and thus decreases insulin signaling. Interacts with GRB7. Interacts with PDPK1. Interacts (via Tyr-1190) with GRB14 (via BPS domain); this interaction protects the tyrosines in the activation loop from dephosphorylation, but promotes dephosphorylation of Tyr-999, this results in decreased interaction with, and phosphorylation of, IRS1. Interacts (via subunit alpha) with ENPP1 (via 485-599 AA); this interaction blocks autophosphorylation. Interacts with PTPRE; this interaction is dependent of Tyr-1185, Tyr-1189 and Tyr-1190 of the INSR. Interacts with STAT5B (via SH2 domain). Interacts with PTPRF. Interacts with ATIC; ATIC together with PRKAA2/AMPK2 and HACD3/PTPLAD1 is proposed to be part of a signaling netwok regulating INSR autophosphorylation and endocytosis (By similarity). Interacts with the cone snail venom insulin Con-Ins G1 (PubMed:27617429).</text>
</comment>
<comment type="interaction">
<interactant intactId="EBI-475899"/>
<interactant intactId="EBI-2361824">
<id>Q99490</id>
<label>AGAP2</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-475899"/>
<interactant intactId="EBI-3197846">
<id>P22413</id>
<label>ENPP1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-475899"/>
<interactant intactId="EBI-80275">
<id>Q13322</id>
<label>GRB10</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-475899"/>
<interactant intactId="EBI-7902275">
<id>P05019</id>
<label>IGF1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-475899"/>
<interactant intactId="EBI-3989070">
<id>P01317</id>
<label>INS</label>
</interactant>
<organismsDiffer>true</organismsDiffer>
<experiments>5</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-475899"/>
<interactant intactId="EBI-517592">
<id>P35568</id>
<label>IRS1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-475899"/>
<interactant intactId="EBI-520230">
<id>P35570</id>
<label>Irs1</label>
</interactant>
<organismsDiffer>true</organismsDiffer>
<experiments>5</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-475899"/>
<interactant intactId="EBI-948001">
<id>Q15323</id>
<label>KRT31</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-475899"/>
<interactant intactId="EBI-79464">
<id>P27986</id>
<label>PIK3R1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-475899"/>
<interactant intactId="EBI-79387">
<id>P19174</id>
<label>PLCG1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>9</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-475899"/>
<interactant intactId="EBI-968788">
<id>P18031</id>
<label>PTPN1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>33</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-475899"/>
<interactant intactId="EBI-297779">
<id>Q06124</id>
<label>PTPN11</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-475899"/>
<interactant intactId="EBI-310491">
<id>Q9NRF2</id>
<label>SH2B1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>6</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-475899"/>
<interactant intactId="EBI-78835">
<id>P29353</id>
<label>SHC1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="subcellular location">
<subcellularLocation>
<location>Cell membrane</location>
<topology>Single-pass type I membrane protein</topology>
</subcellularLocation>
</comment>
<comment type="alternative products">
<event type="alternative splicing"/>
<isoform>
<id>P06213-1</id>
<name>Long</name>
<name>HIR-B</name>
<sequence type="displayed"/>
</isoform>
<isoform>
<id>P06213-2</id>
<name>Short</name>
<name>HIR-A</name>
<sequence type="described" ref="VSP_002898"/>
</isoform>
</comment>
<comment type="tissue specificity">
<text evidence="20 76 118 122">Isoform Long and isoform Short are predominantly expressed in tissue targets of insulin metabolic effects: liver, adipose tissue and skeletal muscle but are also expressed in the peripheral nerve, kidney, pulmonary alveoli, pancreatic acini, placenta vascular endothelium, fibroblasts, monocytes, granulocytes, erythrocytes and skin. Isoform Short is preferentially expressed in fetal cells such as fetal fibroblasts, muscle, liver and kidney. Found as a hybrid receptor with IGF1R in muscle, heart, kidney, adipose tissue, skeletal muscle, hepatoma, fibroblasts, spleen and placenta (at protein level). Overexpressed in several tumors, including breast, colon, lung, ovary, and thyroid carcinomas.</text>
</comment>
<comment type="domain">
<text evidence="53 65 74">The tetrameric insulin receptor binds insulin via non-identical regions from two alpha chains, primarily via the C-terminal region of the first INSR alpha chain. Residues from the leucine-rich N-terminus of the other INSR alpha chain also contribute to this insulin binding site. A secondary insulin-binding site is formed by residues at the junction of fibronectin type-III domain 1 and 2.</text>
</comment>
<comment type="PTM">
<text evidence="41 52 62 63 74 85">After being transported from the endoplasmic reticulum to the Golgi apparatus, the single glycosylated precursor is further glycosylated and then cleaved, followed by its transport to the plasma membrane.</text>
</comment>
<comment type="PTM">
<text evidence="24 36 39 48 49 57 58 87 121">Autophosphorylated on tyrosine residues in response to insulin. Phosphorylation of Tyr-999 is required for binding to IRS1, SHC1 and STAT5B. Dephosphorylated by PTPRE at Tyr-999, Tyr-1185, Tyr-1189 and Tyr-1190. Dephosphorylated by PTPRF and PTPN1. Dephosphorylated by PTPN2; down-regulates insulin-induced signaling.</text>
</comment>
<comment type="disease" evidence="21 31 54 69 75 104">
<disease id="DI-02242">
<name>Rabson-Mendenhall syndrome</name>
<acronym>RMS</acronym>
<description>Severe insulin resistance syndrome characterized by insulin-resistant diabetes mellitus with pineal hyperplasia and somatic abnormalities. Typical features include coarse, senile-appearing facies, dental and skin abnormalities, abdominal distension, and phallic enlargement. Inheritance is autosomal recessive.</description>
<dbReference type="MIM" id="262190"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="disease" evidence="31 35 38 45 55 75 77 82 91 94 98 105 108 112 119 120 124">
<disease id="DI-01890">
<name>Leprechaunism</name>
<acronym>LEPRCH</acronym>
<description>Represents the most severe form of insulin resistance syndrome, characterized by intrauterine and postnatal growth retardation and death in early infancy. Inheritance is autosomal recessive.</description>
<dbReference type="MIM" id="246200"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="disease" evidence="40 46 93">
<disease id="DI-02060">
<name>Diabetes mellitus, non-insulin-dependent</name>
<acronym>NIDDM</acronym>
<description>A multifactorial disorder of glucose homeostasis caused by a lack of sensitivity to the body's own insulin. Affected individuals usually have an obese body habitus and manifestations of a metabolic syndrome characterized by diabetes, insulin resistance, hypertension and hypertriglyceridemia. The disease results in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.</description>
<dbReference type="MIM" id="125853"/>
</disease>
<text>The gene represented in this entry may be involved in disease pathogenesis.</text>
</comment>
<comment type="disease" evidence="42">
<disease id="DI-01583">
<name>Familial hyperinsulinemic hypoglycemia 5</name>
<acronym>HHF5</acronym>
<description>Familial hyperinsulinemic hypoglycemia [MIM:256450], also referred to as congenital hyperinsulinism, nesidioblastosis, or persistent hyperinsulinemic hypoglycemia of infancy (PPHI), is the most common cause of persistent hypoglycemia in infancy and is due to defective negative feedback regulation of insulin secretion by low glucose levels.</description>
<dbReference type="MIM" id="609968"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="disease" evidence="23 27 32 38 44 66 67 70 75 78 88 100 103 104 106 116">
<disease id="DI-01828">
<name>Insulin-resistant diabetes mellitus with acanthosis nigricans type A</name>
<acronym>IRAN type A</acronym>
<description>Characterized by the association of severe insulin resistance (manifested by marked hyperinsulinemia and a failure to respond to exogenous insulin) with the skin lesion acanthosis nigricans and ovarian hyperandrogenism in adolescent female subjects. Women frequently present with hirsutism, acne, amenorrhea or oligomenorrhea, and virilization. This syndrome is different from the type B that has been demonstrated to be secondary to the presence of circulating autoantibodies against the insulin receptor.</description>
<dbReference type="MIM" id="610549"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="similarity">
<text evidence="17">Belongs to the protein kinase superfamily. Tyr protein kinase family. Insulin receptor subfamily.</text>
</comment>
<comment type="online information" name="Wikipedia">
<link uri="https://en.wikipedia.org/wiki/Insulin_receptor"/>
<text>Insulin receptor entry</text>
</comment>
<dbReference type="EC" id="2.7.10.1"/>
<dbReference type="EMBL" id="M10051">
<property type="protein sequence ID" value="AAA59174.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="X02160">
<property type="protein sequence ID" value="CAA26096.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="M32972">
<property type="protein sequence ID" value="AAA59452.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M23100">
<property type="protein sequence ID" value="AAA59452.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M32823">
<property type="protein sequence ID" value="AAA59452.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M32824">
<property type="protein sequence ID" value="AAA59452.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M32825">
<property type="protein sequence ID" value="AAA59452.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M32826">
<property type="protein sequence ID" value="AAA59452.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M32827">
<property type="protein sequence ID" value="AAA59452.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M32828">
<property type="protein sequence ID" value="AAA59452.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M32829">
<property type="protein sequence ID" value="AAA59452.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M32830">
<property type="protein sequence ID" value="AAA59452.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M32831">
<property type="protein sequence ID" value="AAA59452.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M32832">
<property type="protein sequence ID" value="AAA59452.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M32833">
<property type="protein sequence ID" value="AAA59452.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M32834">
<property type="protein sequence ID" value="AAA59452.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M32835">
<property type="protein sequence ID" value="AAA59452.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M32836">
<property type="protein sequence ID" value="AAA59452.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M32837">
<property type="protein sequence ID" value="AAA59452.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M32838">
<property type="protein sequence ID" value="AAA59452.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M32839">
<property type="protein sequence ID" value="AAA59452.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M32840">
<property type="protein sequence ID" value="AAA59452.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M32841">
<property type="protein sequence ID" value="AAA59452.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M32842">
<property type="protein sequence ID" value="AAA59452.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="AC010311">
<property type="status" value="NOT_ANNOTATED_CDS"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="AC010526">
<property type="status" value="NOT_ANNOTATED_CDS"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="AC010606">
<property type="status" value="NOT_ANNOTATED_CDS"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="AC125387">
<property type="status" value="NOT_ANNOTATED_CDS"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="BC117172">
<property type="protein sequence ID" value="AAI17173.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="J03466">
<property type="protein sequence ID" value="AAA59175.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="J05043">
<property type="protein sequence ID" value="AAA59190.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M76592">
<property type="protein sequence ID" value="AAC37604.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="AB208861">
<property type="protein sequence ID" value="BAD92098.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="M24555">
<property type="protein sequence ID" value="AAA59178.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="M29929">
<property type="protein sequence ID" value="AAA59176.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M29930">
<property type="protein sequence ID" value="AAA59177.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M27197">
<property type="protein sequence ID" value="AAA86791.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M27195">
<property type="protein sequence ID" value="AAA86791.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="CCDS" id="CCDS12176.1">
<molecule id="P06213-1"/>
</dbReference>
<dbReference type="CCDS" id="CCDS42487.1">
<molecule id="P06213-2"/>
</dbReference>
<dbReference type="PIR" id="A37348">
<property type="entry name" value="INHUR"/>
</dbReference>
<dbReference type="RefSeq" id="NP_000199.2">
<molecule id="P06213-1"/>
<property type="nucleotide sequence ID" value="NM_000208.3"/>
</dbReference>
<dbReference type="RefSeq" id="NP_001073285.1">
<molecule id="P06213-2"/>
<property type="nucleotide sequence ID" value="NM_001079817.2"/>
</dbReference>
<dbReference type="UniGene" id="Hs.465744"/>
<dbReference type="PDB" id="1GAG">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.70"/>
<property type="chains" value="A=1005-1310"/>
</dbReference>
<dbReference type="PDB" id="1I44">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.40"/>
<property type="chains" value="A=1005-1310"/>
</dbReference>
<dbReference type="PDB" id="1IR3">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.90"/>
<property type="chains" value="A=1005-1310"/>
</dbReference>
<dbReference type="PDB" id="1IRK">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.10"/>
<property type="chains" value="A=1005-1310"/>
</dbReference>
<dbReference type="PDB" id="1P14">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.90"/>
<property type="chains" value="A=1005-1310"/>
</dbReference>
<dbReference type="PDB" id="1RQQ">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.60"/>
<property type="chains" value="A/B=1005-1310"/>
</dbReference>
<dbReference type="PDB" id="2AUH">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.20"/>
<property type="chains" value="A=1005-1310"/>
</dbReference>
<dbReference type="PDB" id="2B4S">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.30"/>
<property type="chains" value="B/D=1005-1310"/>
</dbReference>
<dbReference type="PDB" id="2HR7">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.32"/>
<property type="chains" value="A/B=28-512"/>
</dbReference>
<dbReference type="PDB" id="2MFR">
<property type="method" value="NMR"/>
<property type="chains" value="A=940-988"/>
</dbReference>
<dbReference type="PDB" id="2Z8C">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.25"/>
<property type="chains" value="A=1008-1310"/>
</dbReference>
<dbReference type="PDB" id="3BU3">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.65"/>
<property type="chains" value="A=1005-1310"/>
</dbReference>
<dbReference type="PDB" id="3BU5">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.10"/>
<property type="chains" value="A=1005-1310"/>
</dbReference>
<dbReference type="PDB" id="3BU6">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.95"/>
<property type="chains" value="A=1005-1310"/>
</dbReference>
<dbReference type="PDB" id="3EKK">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.10"/>
<property type="chains" value="A=1005-1310"/>
</dbReference>
<dbReference type="PDB" id="3EKN">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.20"/>
<property type="chains" value="A=1005-1310"/>
</dbReference>
<dbReference type="PDB" id="3ETA">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.60"/>
<property type="chains" value="A/B=1017-1322"/>
</dbReference>
<dbReference type="PDB" id="3W11">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.90"/>
<property type="chains" value="E=28-337, F=731-744"/>
</dbReference>
<dbReference type="PDB" id="3W12">
<property type="method" value="X-ray"/>
<property type="resolution" value="4.30"/>
<property type="chains" value="E=28-337, F=731-744"/>
</dbReference>
<dbReference type="PDB" id="3W13">
<property type="method" value="X-ray"/>
<property type="resolution" value="4.30"/>
<property type="chains" value="E=28-337, F=724-744"/>
</dbReference>
<dbReference type="PDB" id="3W14">
<property type="method" value="X-ray"/>
<property type="resolution" value="4.40"/>
<property type="chains" value="E/F=28-746"/>
</dbReference>
<dbReference type="PDB" id="4IBM">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.80"/>
<property type="chains" value="A/B=1005-1310"/>
</dbReference>
<dbReference type="PDB" id="4OGA">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.50"/>
<property type="chains" value="E=28-337, F=731-744"/>
</dbReference>
<dbReference type="PDB" id="4XLV">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.30"/>
<property type="chains" value="A=983-1310"/>
</dbReference>
<dbReference type="PDB" id="4XSS">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.00"/>
<property type="chains" value="E=28-337"/>
</dbReference>
<dbReference type="PDB" id="4XST">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.00"/>
<property type="chains" value="E=28-337"/>
</dbReference>
<dbReference type="PDB" id="4ZXB">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.30"/>
<property type="chains" value="E=28-956"/>
</dbReference>
<dbReference type="PDB" id="5E1S">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.26"/>
<property type="chains" value="A=1005-1310"/>
</dbReference>
<dbReference type="PDB" id="5HHW">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.79"/>
<property type="chains" value="A=1005-1310"/>
</dbReference>
<dbReference type="PDB" id="5J3H">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.27"/>
<property type="chains" value="E=28-337"/>
</dbReference>
<dbReference type="PDBsum" id="1GAG"/>
<dbReference type="PDBsum" id="1I44"/>
<dbReference type="PDBsum" id="1IR3"/>
<dbReference type="PDBsum" id="1IRK"/>
<dbReference type="PDBsum" id="1P14"/>
<dbReference type="PDBsum" id="1RQQ"/>
<dbReference type="PDBsum" id="2AUH"/>
<dbReference type="PDBsum" id="2B4S"/>
<dbReference type="PDBsum" id="2HR7"/>
<dbReference type="PDBsum" id="2MFR"/>
<dbReference type="PDBsum" id="2Z8C"/>
<dbReference type="PDBsum" id="3BU3"/>
<dbReference type="PDBsum" id="3BU5"/>
<dbReference type="PDBsum" id="3BU6"/>
<dbReference type="PDBsum" id="3EKK"/>
<dbReference type="PDBsum" id="3EKN"/>
<dbReference type="PDBsum" id="3ETA"/>
<dbReference type="PDBsum" id="3W11"/>
<dbReference type="PDBsum" id="3W12"/>
<dbReference type="PDBsum" id="3W13"/>
<dbReference type="PDBsum" id="3W14"/>
<dbReference type="PDBsum" id="4IBM"/>
<dbReference type="PDBsum" id="4OGA"/>
<dbReference type="PDBsum" id="4XLV"/>
<dbReference type="PDBsum" id="4XSS"/>
<dbReference type="PDBsum" id="4XST"/>
<dbReference type="PDBsum" id="4ZXB"/>
<dbReference type="PDBsum" id="5E1S"/>
<dbReference type="PDBsum" id="5HHW"/>
<dbReference type="PDBsum" id="5J3H"/>
<dbReference type="ProteinModelPortal" id="P06213"/>
<dbReference type="SMR" id="P06213"/>
<dbReference type="BioGrid" id="109854">
<property type="interactions" value="77"/>
</dbReference>
<dbReference type="DIP" id="DIP-480N"/>
<dbReference type="IntAct" id="P06213">
<property type="interactions" value="50"/>
</dbReference>
<dbReference type="MINT" id="MINT-1516246"/>
<dbReference type="STRING" id="9606.ENSP00000303830"/>
<dbReference type="BindingDB" id="P06213"/>
<dbReference type="ChEMBL" id="CHEMBL1981"/>
<dbReference type="DrugBank" id="DB08513">
<property type="generic name" value="[4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID"/>
</dbReference>
<dbReference type="DrugBank" id="DB05120">
<property type="generic name" value="AT1391"/>
</dbReference>
<dbReference type="DrugBank" id="DB01306">
<property type="generic name" value="Insulin Aspart"/>
</dbReference>
<dbReference type="DrugBank" id="DB09564">
<property type="generic name" value="Insulin Degludec"/>
</dbReference>
<dbReference type="DrugBank" id="DB01307">
<property type="generic name" value="Insulin Detemir"/>
</dbReference>
<dbReference type="DrugBank" id="DB00047">
<property type="generic name" value="Insulin Glargine"/>
</dbReference>
<dbReference type="DrugBank" id="DB01309">
<property type="generic name" value="Insulin Glulisine"/>
</dbReference>
<dbReference type="DrugBank" id="DB00030">
<property type="generic name" value="Insulin Human"/>
</dbReference>
<dbReference type="DrugBank" id="DB00046">
<property type="generic name" value="Insulin Lispro"/>
</dbReference>
<dbReference type="DrugBank" id="DB00071">
<property type="generic name" value="Insulin Pork"/>
</dbReference>
<dbReference type="DrugBank" id="DB01277">
<property type="generic name" value="Mecasermin"/>
</dbReference>
<dbReference type="DrugBank" id="DB05115">
<property type="generic name" value="NN344"/>
</dbReference>
<dbReference type="GuidetoPHARMACOLOGY" id="1800"/>
<dbReference type="iPTMnet" id="P06213"/>
<dbReference type="PhosphoSitePlus" id="P06213"/>
<dbReference type="BioMuta" id="INSR"/>
<dbReference type="DMDM" id="308153655"/>
<dbReference type="EPD" id="P06213"/>
<dbReference type="MaxQB" id="P06213"/>
<dbReference type="PaxDb" id="P06213"/>
<dbReference type="PeptideAtlas" id="P06213"/>
<dbReference type="PRIDE" id="P06213"/>
<dbReference type="DNASU" id="3643"/>
<dbReference type="Ensembl" id="ENST00000302850">
<molecule id="P06213-1"/>
<property type="protein sequence ID" value="ENSP00000303830"/>
<property type="gene ID" value="ENSG00000171105"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000341500">
<molecule id="P06213-2"/>
<property type="protein sequence ID" value="ENSP00000342838"/>
<property type="gene ID" value="ENSG00000171105"/>
</dbReference>
<dbReference type="GeneID" id="3643"/>
<dbReference type="KEGG" id="hsa:3643"/>
<dbReference type="UCSC" id="uc002mgd.2">
<molecule id="P06213-1"/>
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="CTD" id="3643"/>
<dbReference type="DisGeNET" id="3643"/>
<dbReference type="GeneCards" id="INSR"/>
<dbReference type="H-InvDB" id="HIX0040111"/>
<dbReference type="HGNC" id="HGNC:6091">
<property type="gene designation" value="INSR"/>
</dbReference>
<dbReference type="HPA" id="HPA036302"/>
<dbReference type="HPA" id="HPA036303"/>
<dbReference type="MalaCards" id="INSR"/>
<dbReference type="MIM" id="125853">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="147670">
<property type="type" value="gene"/>
</dbReference>
<dbReference type="MIM" id="246200">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="262190">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="609968">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="610549">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="neXtProt" id="NX_P06213"/>
<dbReference type="OpenTargets" id="ENSG00000171105"/>
<dbReference type="Orphanet" id="263458">
<property type="disease" value="Hyperinsulinism due to INSR deficiency"/>
</dbReference>
<dbReference type="Orphanet" id="2297">
<property type="disease" value="Insulin-resistance syndrome type A"/>
</dbReference>
<dbReference type="Orphanet" id="508">
<property type="disease" value="Leprechaunism"/>
</dbReference>
<dbReference type="Orphanet" id="769">
<property type="disease" value="Rabson-Mendenhall syndrome"/>
</dbReference>
<dbReference type="PharmGKB" id="PA202"/>
<dbReference type="eggNOG" id="KOG4258">
<property type="taxonomic scope" value="Eukaryota"/>
</dbReference>
<dbReference type="eggNOG" id="COG0515">
<property type="taxonomic scope" value="LUCA"/>
</dbReference>
<dbReference type="GeneTree" id="ENSGT00760000118818"/>
<dbReference type="HOGENOM" id="HOG000038045"/>
<dbReference type="HOVERGEN" id="HBG006134"/>
<dbReference type="InParanoid" id="P06213"/>
<dbReference type="KO" id="K04527"/>
<dbReference type="OMA" id="GAAGHLY"/>
<dbReference type="OrthoDB" id="EOG091G00GE"/>
<dbReference type="PhylomeDB" id="P06213"/>
<dbReference type="TreeFam" id="TF351636"/>
<dbReference type="BRENDA" id="2.7.10.1">
<property type="organism ID" value="2681"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-6811558">
<property type="pathway name" value="PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-74713">
<property type="pathway name" value="IRS activation"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-74749">
<property type="pathway name" value="Signal attenuation"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-74751">
<property type="pathway name" value="Insulin receptor signalling cascade"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-74752">
<property type="pathway name" value="Signaling by Insulin receptor"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-77387">
<property type="pathway name" value="Insulin receptor recycling"/>
</dbReference>
<dbReference type="SABIO-RK" id="P06213"/>
<dbReference type="SignaLink" id="P06213"/>
<dbReference type="SIGNOR" id="P06213"/>
<dbReference type="ChiTaRS" id="INSR">
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="EvolutionaryTrace" id="P06213"/>
<dbReference type="GeneWiki" id="Insulin_receptor"/>
<dbReference type="GenomeRNAi" id="3643"/>
<dbReference type="PRO" id="PR:P06213"/>
<dbReference type="Proteomes" id="UP000005640">
<property type="component" value="Chromosome 19"/>
</dbReference>
<dbReference type="Bgee" id="ENSG00000171105"/>
<dbReference type="CleanEx" id="HS_INSR"/>
<dbReference type="ExpressionAtlas" id="P06213">
<property type="expression patterns" value="baseline and differential"/>
</dbReference>
<dbReference type="Genevisible" id="P06213">
<property type="organism ID" value="HS"/>
</dbReference>
<dbReference type="GO" id="GO:0005901">
<property type="term" value="C:caveola"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0010008">
<property type="term" value="C:endosome membrane"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0070062">
<property type="term" value="C:extracellular exosome"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005899">
<property type="term" value="C:insulin receptor complex"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0005887">
<property type="term" value="C:integral component of plasma membrane"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0016020">
<property type="term" value="C:membrane"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0005886">
<property type="term" value="C:plasma membrane"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0043235">
<property type="term" value="C:receptor complex"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="MGI"/>
</dbReference>
<dbReference type="GO" id="GO:0005524">
<property type="term" value="F:ATP binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0005525">
<property type="term" value="F:GTP binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0043559">
<property type="term" value="F:insulin binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0043560">
<property type="term" value="F:insulin receptor substrate binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005009">
<property type="term" value="F:insulin-activated receptor activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0031994">
<property type="term" value="F:insulin-like growth factor I binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0031995">
<property type="term" value="F:insulin-like growth factor II binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0005159">
<property type="term" value="F:insulin-like growth factor receptor binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0043548">
<property type="term" value="F:phosphatidylinositol 3-kinase binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0019904">
<property type="term" value="F:protein domain specific binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="CAFA"/>
</dbReference>
<dbReference type="GO" id="GO:0004713">
<property type="term" value="F:protein tyrosine kinase activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0051425">
<property type="term" value="F:PTB domain binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0004716">
<property type="term" value="F:signal transducer, downstream of receptor, with protein tyrosine kinase activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0000187">
<property type="term" value="P:activation of MAPK activity"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0032147">
<property type="term" value="P:activation of protein kinase activity"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0032148">
<property type="term" value="P:activation of protein kinase B activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0030325">
<property type="term" value="P:adrenal gland development"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0005975">
<property type="term" value="P:carbohydrate metabolic process"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="GO" id="GO:0071363">
<property type="term" value="P:cellular response to growth factor stimulus"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0032869">
<property type="term" value="P:cellular response to insulin stimulus"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0008544">
<property type="term" value="P:epidermis development"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0031017">
<property type="term" value="P:exocrine pancreas development"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0007186">
<property type="term" value="P:G-protein coupled receptor signaling pathway"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0042593">
<property type="term" value="P:glucose homeostasis"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0003007">
<property type="term" value="P:heart morphogenesis"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0008286">
<property type="term" value="P:insulin receptor signaling pathway"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0008584">
<property type="term" value="P:male gonad development"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0030238">
<property type="term" value="P:male sex determination"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0038083">
<property type="term" value="P:peptidyl-tyrosine autophosphorylation"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0018108">
<property type="term" value="P:peptidyl-tyrosine phosphorylation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0030335">
<property type="term" value="P:positive regulation of cell migration"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0008284">
<property type="term" value="P:positive regulation of cell proliferation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0048639">
<property type="term" value="P:positive regulation of developmental growth"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0045740">
<property type="term" value="P:positive regulation of DNA replication"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0046326">
<property type="term" value="P:positive regulation of glucose import"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0045725">
<property type="term" value="P:positive regulation of glycogen biosynthetic process"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0045821">
<property type="term" value="P:positive regulation of glycolytic process"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0043410">
<property type="term" value="P:positive regulation of MAPK cascade"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0051446">
<property type="term" value="P:positive regulation of meiotic cell cycle"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0045840">
<property type="term" value="P:positive regulation of mitotic nuclear division"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0045429">
<property type="term" value="P:positive regulation of nitric oxide biosynthetic process"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0051897">
<property type="term" value="P:positive regulation of protein kinase B signaling"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0001934">
<property type="term" value="P:positive regulation of protein phosphorylation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0060267">
<property type="term" value="P:positive regulation of respiratory burst"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0045893">
<property type="term" value="P:positive regulation of transcription, DNA-templated"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0046777">
<property type="term" value="P:protein autophosphorylation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0051290">
<property type="term" value="P:protein heterotetramerization"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0045995">
<property type="term" value="P:regulation of embryonic development"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:2000194">
<property type="term" value="P:regulation of female gonad development"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0006355">
<property type="term" value="P:regulation of transcription, DNA-templated"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0019087">
<property type="term" value="P:transformation of host cell by virus"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="CDD" id="cd00063">
<property type="entry name" value="FN3"/>
<property type="match status" value="2"/>
</dbReference>
<dbReference type="Gene3D" id="2.60.40.10">
<property type="match status" value="3"/>
</dbReference>
<dbReference type="Gene3D" id="3.80.20.20">
<property type="match status" value="3"/>
</dbReference>
<dbReference type="InterPro" id="IPR003961">
<property type="entry name" value="FN3_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR006211">
<property type="entry name" value="Furin-like_Cys-rich_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR006212">
<property type="entry name" value="Furin_repeat"/>
</dbReference>
<dbReference type="InterPro" id="IPR009030">
<property type="entry name" value="Growth_fac_rcpt_"/>
</dbReference>
<dbReference type="InterPro" id="IPR013783">
<property type="entry name" value="Ig-like_fold"/>
</dbReference>
<dbReference type="InterPro" id="IPR011009">
<property type="entry name" value="Kinase-like_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR032675">
<property type="entry name" value="L_dom-like"/>
</dbReference>
<dbReference type="InterPro" id="IPR000719">
<property type="entry name" value="Prot_kinase_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR017441">
<property type="entry name" value="Protein_kinase_ATP_BS"/>
</dbReference>
<dbReference type="InterPro" id="IPR000494">
<property type="entry name" value="Rcpt_L-dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR001245">
<property type="entry name" value="Ser-Thr/Tyr_kinase_cat_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR008266">
<property type="entry name" value="Tyr_kinase_AS"/>
</dbReference>
<dbReference type="InterPro" id="IPR020635">
<property type="entry name" value="Tyr_kinase_cat_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR016246">
<property type="entry name" value="Tyr_kinase_insulin-like_rcpt"/>
</dbReference>
<dbReference type="InterPro" id="IPR002011">
<property type="entry name" value="Tyr_kinase_rcpt_2_CS"/>
</dbReference>
<dbReference type="Pfam" id="PF00757">
<property type="entry name" value="Furin-like"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF07714">
<property type="entry name" value="Pkinase_Tyr"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF01030">
<property type="entry name" value="Recep_L_domain"/>
<property type="match status" value="2"/>
</dbReference>
<dbReference type="PIRSF" id="PIRSF000620">
<property type="entry name" value="Insulin_receptor"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PRINTS" id="PR00109">
<property type="entry name" value="TYRKINASE"/>
</dbReference>
<dbReference type="SMART" id="SM00060">
<property type="entry name" value="FN3"/>
<property type="match status" value="3"/>
</dbReference>
<dbReference type="SMART" id="SM00261">
<property type="entry name" value="FU"/>
<property type="match status" value="2"/>
</dbReference>
<dbReference type="SMART" id="SM00219">
<property type="entry name" value="TyrKc"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF49265">
<property type="entry name" value="SSF49265"/>
<property type="match status" value="4"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF52058">
<property type="entry name" value="SSF52058"/>
<property type="match status" value="2"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF56112">
<property type="entry name" value="SSF56112"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF57184">
<property type="entry name" value="SSF57184"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS50853">
<property type="entry name" value="FN3"/>
<property type="match status" value="2"/>
</dbReference>
<dbReference type="PROSITE" id="PS00107">
<property type="entry name" value="PROTEIN_KINASE_ATP"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS50011">
<property type="entry name" value="PROTEIN_KINASE_DOM"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS00109">
<property type="entry name" value="PROTEIN_KINASE_TYR"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS00239">
<property type="entry name" value="RECEPTOR_TYR_KIN_II"/>
<property type="match status" value="1"/>
</dbReference>
<proteinExistence type="evidence at protein level"/>
<keyword id="KW-0002">3D-structure</keyword>
<keyword id="KW-0025">Alternative splicing</keyword>
<keyword id="KW-0067">ATP-binding</keyword>
<keyword id="KW-0119">Carbohydrate metabolism</keyword>
<keyword id="KW-1003">Cell membrane</keyword>
<keyword id="KW-0165">Cleavage on pair of basic residues</keyword>
<keyword id="KW-0181">Complete proteome</keyword>
<keyword id="KW-0219">Diabetes mellitus</keyword>
<keyword id="KW-0903">Direct protein sequencing</keyword>
<keyword id="KW-0225">Disease mutation</keyword>
<keyword id="KW-1015">Disulfide bond</keyword>
<keyword id="KW-0325">Glycoprotein</keyword>
<keyword id="KW-0418">Kinase</keyword>
<keyword id="KW-0472">Membrane</keyword>
<keyword id="KW-0547">Nucleotide-binding</keyword>
<keyword id="KW-0597">Phosphoprotein</keyword>
<keyword id="KW-0621">Polymorphism</keyword>
<keyword id="KW-0675">Receptor</keyword>
<keyword id="KW-1185">Reference proteome</keyword>
<keyword id="KW-0677">Repeat</keyword>
<keyword id="KW-0732">Signal</keyword>
<keyword id="KW-0808">Transferase</keyword>
<keyword id="KW-0812">Transmembrane</keyword>
<keyword id="KW-1133">Transmembrane helix</keyword>
<keyword id="KW-0829">Tyrosine-protein kinase</keyword>
<feature type="signal peptide" evidence="72 85 101">
<location>
<begin position="1"/>
<end position="27"/>
</location>
</feature>
<feature type="chain" description="Insulin receptor subunit alpha" id="PRO_0000016687">
<location>
<begin position="28"/>
<end position="758"/>
</location>
</feature>
<feature type="chain" description="Insulin receptor subunit beta" id="PRO_0000016689">
<location>
<begin position="763"/>
<end position="1382"/>
</location>
</feature>
<feature type="topological domain" description="Extracellular" evidence="128">
<location>
<begin position="28"/>
<end position="758"/>
</location>
</feature>
<feature type="topological domain" description="Extracellular" evidence="128">
<location>
<begin position="763"/>
<end position="956"/>
</location>
</feature>
<feature type="transmembrane region" description="Helical" evidence="16">
<location>
<begin position="957"/>
<end position="979"/>
</location>
</feature>
<feature type="topological domain" description="Cytoplasmic" evidence="128">
<location>
<begin position="980"/>
<end position="1382"/>
</location>
</feature>
<feature type="domain" description="Fibronectin type-III 1" evidence="18">
<location>
<begin position="624"/>
<end position="726"/>
</location>
</feature>
<feature type="domain" description="Fibronectin type-III 2" evidence="18">
<location>
<begin position="757"/>
<end position="842"/>
</location>
</feature>
<feature type="domain" description="Fibronectin type-III 3" evidence="18">
<location>
<begin position="853"/>
<end position="947"/>
</location>
</feature>
<feature type="domain" description="Protein kinase" evidence="17">
<location>
<begin position="1023"/>
<end position="1298"/>
</location>
</feature>
<feature type="nucleotide phosphate-binding region" description="ATP" evidence="17 57">
<location>
<begin position="1104"/>
<end position="1110"/>
</location>
</feature>
<feature type="nucleotide phosphate-binding region" description="ATP" evidence="17 57">
<location>
<begin position="1163"/>
<end position="1164"/>
</location>
</feature>
<feature type="region of interest" description="Insulin-binding">
<location>
<begin position="733"/>
<end position="741"/>
</location>
</feature>
<feature type="region of interest" description="Important for interaction with IRS1, SHC1 and STAT5B" evidence="123">
<location>
<position position="999"/>
</location>
</feature>
<feature type="region of interest" description="PIK3R1-binding">
<location>
<begin position="1361"/>
<end position="1364"/>
</location>
</feature>
<feature type="compositionally biased region" description="Leu-rich">
<location>
<begin position="28"/>
<end position="174"/>
</location>
</feature>
<feature type="compositionally biased region" description="Cys-rich">
<location>
<begin position="182"/>
<end position="339"/>
</location>
</feature>
<feature type="active site" description="Proton donor/acceptor" evidence="121">
<location>
<position position="1159"/>
</location>
</feature>
<feature type="binding site" description="ATP" evidence="17 57">
<location>
<position position="1033"/>
</location>
</feature>
<feature type="binding site" description="ATP" evidence="17 57">
<location>
<position position="1057"/>
</location>
</feature>
<feature type="binding site" description="ATP" evidence="17 57">
<location>
<position position="1177"/>
</location>
</feature>
<feature type="site" description="Insulin-binding" evidence="128">
<location>
<position position="66"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="13">
<location>
<position position="400"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine" evidence="13">
<location>
<position position="401"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="13">
<location>
<position position="407"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="128">
<location>
<position position="992"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="129">
<location>
<position position="999"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="128">
<location>
<position position="1011"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="39 48 49 57 58 87 121">
<location>
<position position="1185"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="39 48 49 57 58 87 121">
<location>
<position position="1189"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="39 48 49 57 58 87 121">
<location>
<position position="1190"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="129">
<location>
<position position="1355"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="129">
<location>
<position position="1361"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="52 74 85">
<location>
<position position="43"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="52 74">
<location>
<position position="52"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="16">
<location>
<position position="105"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="52 74">
<location>
<position position="138"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="52 62 74">
<location>
<position position="242"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="52 74">
<location>
<position position="282"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="16">
<location>
<position position="322"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="52">
<location>
<position position="364"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="52">
<location>
<position position="424"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="52 63">
<location>
<position position="445"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="41 62">
<location>
<position position="541"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="16">
<location>
<position position="633"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="16">
<location>
<position position="651"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="16">
<location>
<position position="698"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="85">
<location>
<position position="769"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="16">
<location>
<position position="782"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="63">
<location>
<position position="920"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="16">
<location>
<position position="933"/>
</location>
</feature>
<feature type="disulfide bond">
<location>
<begin position="35"/>
<end position="53"/>
</location>
</feature>
<feature type="disulfide bond">
<location>
<begin position="153"/>
<end position="182"/>
</location>
</feature>
<feature type="disulfide bond">
<location>
<begin position="186"/>
<end position="209"/>
</location>
</feature>
<feature type="disulfide bond">
<location>
<begin position="196"/>
<end position="215"/>
</location>
</feature>
<feature type="disulfide bond">
<location>
<begin position="219"/>
<end position="228"/>
</location>
</feature>
<feature type="disulfide bond">
<location>
<begin position="223"/>
<end position="234"/>
</location>
</feature>
<feature type="disulfide bond">
<location>
<begin position="235"/>
<end position="243"/>
</location>
</feature>
<feature type="disulfide bond">
<location>
<begin position="239"/>
<end position="252"/>
</location>
</feature>
<feature type="disulfide bond">
<location>
<begin position="255"/>
<end position="264"/>
</location>
</feature>
<feature type="disulfide bond">
<location>
<begin position="268"/>
<end position="280"/>
</location>
</feature>
<feature type="disulfide bond">
<location>
<begin position="286"/>
<end position="311"/>
</location>
</feature>
<feature type="disulfide bond">
<location>
<begin position="293"/>
<end position="301"/>
</location>
</feature>
<feature type="disulfide bond">
<location>
<begin position="315"/>
<end position="328"/>
</location>
</feature>
<feature type="disulfide bond">
<location>
<begin position="331"/>
<end position="335"/>
</location>
</feature>
<feature type="disulfide bond">
<location>
<begin position="339"/>
<end position="360"/>
</location>
</feature>
<feature type="disulfide bond" evidence="41">
<location>
<begin position="462"/>
<end position="495"/>
</location>
</feature>
<feature type="disulfide bond" description="Interchain" evidence="41">
<location>
<position position="551"/>
</location>
</feature>
<feature type="disulfide bond">
<location>
<begin position="674"/>
<end position="899"/>
</location>
</feature>
<feature type="disulfide bond">
<location>
<begin position="825"/>
<end position="834"/>
</location>
</feature>
<feature type="splice variant" description="In isoform Short." id="VSP_002898" evidence="125 126 127">
<location>
<begin position="745"/>
<end position="756"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs7508518." id="VAR_058395" evidence="43 71 73 80 81 84 85 89">
<original>A</original>
<variation>G</variation>
<location>
<position position="2"/>
</location>
</feature>
<feature type="sequence variant" description="In RMS; impairs transport to the plasma membrane and reduces the affinity to bind insulin; dbSNP:rs121913143." id="VAR_004079" evidence="69 75">
<original>N</original>
<variation>K</variation>
<location>
<position position="42"/>
</location>
</feature>
<feature type="sequence variant" description="In LEPRCH; Verona-1; dbSNP:rs121913152." id="VAR_004080" evidence="45">
<original>V</original>
<variation>A</variation>
<location>
<position position="55"/>
</location>
</feature>
<feature type="sequence variant" description="In LEPRCH; Helmond; inhibits processing and transport; dbSNP:rs52836744." id="VAR_004081" evidence="55">
<original>G</original>
<variation>R</variation>
<location>
<position position="58"/>
</location>
</feature>
<feature type="sequence variant" description="In IRAN type A." id="VAR_015907" evidence="116">
<original>D</original>
<variation>G</variation>
<location>
<position position="86"/>
</location>
</feature>
<feature type="sequence variant" description="In IRAN type A." id="VAR_015908" evidence="116">
<original>L</original>
<variation>P</variation>
<location>
<position position="89"/>
</location>
</feature>
<feature type="sequence variant" description="In LEPRCH; Atlanta-1; abolishes insulin binding; dbSNP:rs121913153." id="VAR_004082" evidence="31 108">
<original>R</original>
<variation>P</variation>
<location>
<position position="113"/>
</location>
</feature>
<feature type="sequence variant" description="In LEPRCH; markedly impairs insulin binding." id="VAR_015909" evidence="31">
<original>A</original>
<variation>V</variation>
<location>
<position position="119"/>
</location>
</feature>
<feature type="sequence variant" description="In LEPRCH; inhibits receptor processing." id="VAR_031518" evidence="38">
<original>L</original>
<variation>Q</variation>
<location>
<position position="120"/>
</location>
</feature>
<feature type="sequence variant" description="In LEPRCH; mild; dbSNP:rs121913159." id="VAR_015539" evidence="94 105">
<original>I</original>
<variation>M</variation>
<location>
<position position="146"/>
</location>
</feature>
<feature type="sequence variant" description="In IRAN type A." id="VAR_015910" evidence="23">
<original>V</original>
<variation>L</variation>
<location>
<position position="167"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs1051692." id="VAR_058396" evidence="84">
<original>Y</original>
<variation>H</variation>
<location>
<position position="171"/>
</location>
</feature>
<feature type="sequence variant" description="In Ins resistance; severe; dbSNP:rs749094324." id="VAR_004083" evidence="99">
<original>P</original>
<variation>L</variation>
<location>
<position position="220"/>
</location>
</feature>
<feature type="sequence variant" description="In a gastric adenocarcinoma sample; somatic mutation." id="VAR_041429" evidence="56">
<original>C</original>
<variation>R</variation>
<location>
<position position="228"/>
</location>
</feature>
<feature type="sequence variant" description="In RMS and LEPRCH; Winnipeg; may impair receptor processing; dbSNP:rs121913145." id="VAR_004084" evidence="54 75">
<original>H</original>
<variation>R</variation>
<location>
<position position="236"/>
</location>
</feature>
<feature type="sequence variant" description="In LEPRCH; Geldeimalsen; dbSNP:rs121913141." id="VAR_004085" evidence="77">
<original>L</original>
<variation>P</variation>
<location>
<position position="260"/>
</location>
</feature>
<feature type="sequence variant" description="In IRAN type A; inhibits receptor internalization." id="VAR_015540" evidence="32">
<original>R</original>
<variation>C</variation>
<location>
<position position="279"/>
</location>
</feature>
<feature type="sequence variant" description="In IRAN type A; interferes with receptor processing." id="VAR_031519" evidence="38">
<original>R</original>
<variation>H</variation>
<location>
<position position="279"/>
</location>
</feature>
<feature type="sequence variant" description="In IRAN type A." id="VAR_015911" evidence="27">
<original>C</original>
<variation>Y</variation>
<location>
<position position="280"/>
</location>
</feature>
<feature type="sequence variant" description="In LEPRCH." id="VAR_015912" evidence="124">
<original>C</original>
<variation>Y</variation>
<location>
<position position="301"/>
</location>
</feature>
<feature type="sequence variant" description="In LEPRCH; abolishes insulin binding." id="VAR_015913" evidence="31 91 112">
<location>
<position position="308"/>
</location>
</feature>
<feature type="sequence variant" description="In RMS and LEPRCH." id="VAR_015914" evidence="38 104">
<original>S</original>
<variation>L</variation>
<location>
<position position="350"/>
</location>
</feature>
<feature type="sequence variant" description="In LEPRCH." id="VAR_015541" evidence="35">
<location>
<position position="362"/>
</location>
</feature>
<feature type="sequence variant" description="In RMS; may impair receptor processing; dbSNP:rs764221583." id="VAR_031520" evidence="54">
<original>G</original>
<variation>S</variation>
<location>
<position position="386"/>
</location>
</feature>
<feature type="sequence variant" description="In LEPRCH; Verona-1; dbSNP:rs267607184." id="VAR_004086" evidence="45">
<original>G</original>
<variation>R</variation>
<location>
<position position="393"/>
</location>
</feature>
<feature type="sequence variant" description="In IRAN type A; dbSNP:rs121913142." id="VAR_004087" evidence="106">
<original>F</original>
<variation>V</variation>
<location>
<position position="409"/>
</location>
</feature>
<feature type="sequence variant" description="In LEPRCH; impairs transport of the receptor to the cell surface; dbSNP:rs121913158." id="VAR_015542" evidence="98">
<original>W</original>
<variation>S</variation>
<location>
<position position="439"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs1051691." id="VAR_015915" evidence="84">
<original>I</original>
<variation>T</variation>
<location>
<position position="448"/>
</location>
</feature>
<feature type="sequence variant" description="In LEPRCH; partially inhibits receptor processing and autophosphorylation; strongly impairs ERK phosphorylation; induces wild-type levels of IRS-1 phosphorylation; dbSNP:rs121913160." id="VAR_031521" evidence="38">
<original>N</original>
<variation>D</variation>
<location>
<position position="458"/>
</location>
</feature>
<feature type="sequence variant" description="In LEPRCH; ARK-1; dbSNP:rs28933083." id="VAR_004088" evidence="82">
<original>K</original>
<variation>E</variation>
<location>
<position position="487"/>
</location>
</feature>
<feature type="sequence variant" description="In IRAN type A; dbSNP:rs28933085." id="VAR_004089" evidence="75">
<original>N</original>
<variation>S</variation>
<location>
<position position="489"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs1131851." id="VAR_015916" evidence="84">
<original>Q</original>
<variation>K</variation>
<location>
<position position="492"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs55906835." id="VAR_041430" evidence="56">
<original>Q</original>
<variation>R</variation>
<location>
<position position="695"/>
</location>
</feature>
<feature type="sequence variant" description="In IRAN type A; dbSNP:rs121913138." id="VAR_004090" evidence="88">
<original>R</original>
<variation>S</variation>
<location>
<position position="762"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs35045353." id="VAR_041431" evidence="56">
<original>G</original>
<variation>S</variation>
<location>
<position position="811"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs2162771." id="VAR_055986">
<original>P</original>
<variation>L</variation>
<location>
<position position="830"/>
</location>
</feature>
<feature type="sequence variant" description="In NIDDM; dbSNP:rs182552223." id="VAR_015917" evidence="93">
<original>T</original>
<variation>A</variation>
<location>
<position position="858"/>
</location>
</feature>
<feature type="sequence variant" description="In LEPRCH; abolishes insulin binding." id="VAR_015918" evidence="31">
<original>I</original>
<variation>T</variation>
<location>
<position position="925"/>
</location>
</feature>
<feature type="sequence variant" description="In LEPRCH; markedly impairs insulin binding." id="VAR_015919" evidence="31">
<original>R</original>
<variation>W</variation>
<location>
<position position="926"/>
</location>
</feature>
<feature type="sequence variant" description="In LEPRCH; impaired receptor processing." id="VAR_015920" evidence="120">
<original>T</original>
<variation>M</variation>
<location>
<position position="937"/>
</location>
</feature>
<feature type="sequence variant" description="In RMS; reduces insulin binding." id="VAR_015921" evidence="31">
<original>P</original>
<variation>T</variation>
<location>
<position position="997"/>
</location>
</feature>
<feature type="sequence variant" description="Rare polymorphism; dbSNP:rs1799816." id="VAR_004091" evidence="56 104 109 111 117">
<original>V</original>
<variation>M</variation>
<location>
<position position="1012"/>
</location>
</feature>
<feature type="sequence variant" description="In IRAN type A; dbSNP:rs121913148." id="VAR_004092" evidence="67">
<original>R</original>
<variation>Q</variation>
<location>
<position position="1020"/>
</location>
</feature>
<feature type="sequence variant" id="VAR_015922" evidence="113">
<original>I</original>
<variation>F</variation>
<location>
<position position="1023"/>
</location>
</feature>
<feature type="sequence variant" description="In IRAN type A; dbSNP:rs121913135." id="VAR_004093" evidence="78">
<original>G</original>
<variation>V</variation>
<location>
<position position="1035"/>
</location>
</feature>
<feature type="sequence variant" description="In IRAN type A." id="VAR_015923" evidence="23">
<original>A</original>
<variation>V</variation>
<location>
<position position="1055"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs56395521." id="VAR_041432" evidence="56">
<original>L</original>
<variation>V</variation>
<location>
<position position="1065"/>
</location>
</feature>
<feature type="sequence variant" description="In IRAN type A." id="VAR_004094" evidence="100">
<original>A</original>
<variation>D</variation>
<location>
<position position="1075"/>
</location>
</feature>
<feature type="sequence variant" description="In a NIDDM subject." id="VAR_015924" evidence="68">
<original>K</original>
<variation>E</variation>
<location>
<position position="1095"/>
</location>
</feature>
<feature type="sequence variant" description="In LEPRCH." id="VAR_015925" evidence="38 119">
<original>R</original>
<variation>W</variation>
<location>
<position position="1119"/>
</location>
</feature>
<feature type="sequence variant" description="In RMS; reduces insulin binding." id="VAR_015926" evidence="21 31">
<original>I</original>
<variation>T</variation>
<location>
<position position="1143"/>
</location>
</feature>
<feature type="sequence variant" description="In NIDDM." id="VAR_015927" evidence="40">
<original>R</original>
<variation>Q</variation>
<location>
<position position="1158"/>
</location>
</feature>
<feature type="sequence variant" description="In RMS; abolishes insulin binding; dbSNP:rs111993466." id="VAR_015928" evidence="21 31">
<original>R</original>
<variation>W</variation>
<location>
<position position="1158"/>
</location>
</feature>
<feature type="sequence variant" description="In IRAN type A; dbSNP:rs28933084." id="VAR_004095" evidence="70">
<original>A</original>
<variation>T</variation>
<location>
<position position="1161"/>
</location>
</feature>
<feature type="sequence variant" description="In IRAN type A; impairs proteolytic processing; dbSNP:rs121913154." id="VAR_004096" evidence="97">
<original>A</original>
<variation>E</variation>
<location>
<position position="1162"/>
</location>
</feature>
<feature type="sequence variant" description="In a patient with insulin resistance; dbSNP:rs121913157." id="VAR_004097" evidence="59">
<original>M</original>
<variation>I</variation>
<location>
<position position="1180"/>
</location>
</feature>
<feature type="sequence variant" description="In NIDDM; dbSNP:rs121913150." id="VAR_004098" evidence="46">
<original>R</original>
<variation>Q</variation>
<location>
<position position="1191"/>
</location>
</feature>
<feature type="sequence variant" description="In HHF5 and IRAN type A; interferes with kinase activation by insulin; dbSNP:rs28933086." id="VAR_015929" evidence="42 96 103">
<original>R</original>
<variation>Q</variation>
<location>
<position position="1201"/>
</location>
</feature>
<feature type="sequence variant" description="In LEPRCH and RMS; reduces insulin binding possibly due to reduced receptor levels on the cell surface." id="VAR_015930" evidence="31 124">
<original>R</original>
<variation>W</variation>
<location>
<position position="1201"/>
</location>
</feature>
<feature type="sequence variant" description="In IRAN type A; moderate." id="VAR_004099" evidence="44 104">
<original>P</original>
<variation>L</variation>
<location>
<position position="1205"/>
</location>
</feature>
<feature type="sequence variant" description="In IRAN type A; accelerates degradation of the protein and impairs kinase activity." id="VAR_015931" evidence="95">
<original>E</original>
<variation>D</variation>
<location>
<position position="1206"/>
</location>
</feature>
<feature type="sequence variant" description="In LEPRCH." id="VAR_015932" evidence="119">
<original>E</original>
<variation>K</variation>
<location>
<position position="1206"/>
</location>
</feature>
<feature type="sequence variant" description="In IRAN type A; accelerates degradation of the protein and impairs kinase activity; dbSNP:rs52800171." id="VAR_004100" evidence="95 107">
<original>W</original>
<variation>L</variation>
<location>
<position position="1220"/>
</location>
</feature>
<feature type="sequence variant" description="In IRAN type A; dbSNP:rs121913140." id="VAR_004101" evidence="66">
<original>W</original>
<variation>S</variation>
<location>
<position position="1227"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs55875349." id="VAR_041433" evidence="56">
<original>T</original>
<variation>A</variation>
<location>
<position position="1282"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs13306449." id="VAR_015933" evidence="93">
<original>Y</original>
<variation>C</variation>
<location>
<position position="1361"/>
</location>
</feature>
<feature type="sequence variant" description="In IRAN type A; dbSNP:rs52826008." id="VAR_015934" evidence="104">
<original>R</original>
<variation>Q</variation>
<location>
<position position="1378"/>
</location>
</feature>
<feature type="mutagenesis site" description="Reduces interaction with IRS1 but has no effect on interaction with SHC1." evidence="92">
<original>L</original>
<variation>A</variation>
<location>
<position position="991"/>
</location>
</feature>
<feature type="mutagenesis site" description="Reduces interaction with IRS1 but has no effect on interaction with SHC1." evidence="92">
<original>Y</original>
<variation>A</variation>
<location>
<position position="992"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes interaction with IRS1. Severely disrupts, but does not abolish interaction with SHC1." evidence="92">
<original>NP</original>
<variation>AA</variation>
<location>
<begin position="996"/>
<end position="997"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes interaction with IRS1 and significantly reduces interaction with SHC1. Has no effect on interaction with PIK3R1." evidence="90 92">
<original>N</original>
<variation>A</variation>
<location>
<position position="996"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes interaction with IRS1 and significantly reduces interaction with SHC1. Has no effect on interaction with PIK3R1." evidence="90 92">
<original>P</original>
<variation>A</variation>
<location>
<position position="997"/>
</location>
</feature>
<feature type="mutagenesis site" description="Does not affect interaction with IRS1, SHC1 or PIK3R1." evidence="90">
<original>E</original>
<variation>A</variation>
<location>
<position position="998"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes interaction with IRS1 and SHC1." evidence="83 90 92 123">
<original>Y</original>
<variation>E</variation>
<location>
<position position="999"/>
</location>
</feature>
<feature type="mutagenesis site" description="Has no effect on insulin-stimulated autophosphorylation, but inhibits the biological activity of the receptor. Abolishes interaction with IRS1 and almost completely prevents interaction with SHC1. Has no effect on interaction with PIK3R1. Abolishes interaction with STAT5B." evidence="83 90 92 123">
<original>Y</original>
<variation>F</variation>
<location>
<position position="999"/>
</location>
</feature>
<feature type="mutagenesis site" description="Severely reduces interaction with SHC1. Has no effect on interaction with IRS1." evidence="92">
<original>L</original>
<variation>A</variation>
<variation>R</variation>
<location>
<position position="1000"/>
</location>
</feature>
<feature type="mutagenesis site" description="Reduces interaction with IRS1 but has no effect on interaction with SHC1." evidence="92">
<original>A</original>
<variation>D</variation>
<location>
<position position="1002"/>
</location>
</feature>
<feature type="mutagenesis site" description="Increases kinase activity." evidence="37">
<original>Y</original>
<variation>A</variation>
<location>
<position position="1011"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes the kinase activity and abolishes interaction with IRS1, SHC1, GRB7 and PIK3R1." evidence="25 86 90">
<original>K</original>
<variation>A</variation>
<location>
<position position="1057"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes the kinase activity." evidence="25 86 90">
<original>K</original>
<variation>M</variation>
<variation>R</variation>
<location>
<position position="1057"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of kinase activity." evidence="29">
<original>D</original>
<variation>N</variation>
<location>
<position position="1159"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of kinase activity." evidence="29">
<original>R</original>
<variation>Q</variation>
<location>
<position position="1163"/>
</location>
</feature>
<feature type="mutagenesis site" description="Reduced interaction with GRB7." evidence="25">
<original>Y</original>
<variation>F</variation>
<location>
<position position="1189"/>
</location>
</feature>
<feature type="mutagenesis site" description="Strongly reduced interaction with GRB7." evidence="25">
<original>Y</original>
<variation>F</variation>
<location>
<position position="1190"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 19; AA sequence." ref="19" evidence="128">
<original>D</original>
<variation>N</variation>
<location>
<position position="601"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 19; AA sequence." ref="19" evidence="128">
<original>P</original>
<variation>E</variation>
<location>
<position position="830"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 2; CAA26096." ref="2" evidence="128">
<original>K</original>
<variation>N</variation>
<location>
<position position="1278"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="33"/>
<end position="42"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="45"/>
<end position="50"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="53"/>
<end position="65"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="70"/>
<end position="72"/>
</location>
</feature>
<feature type="turn" evidence="5">
<location>
<begin position="73"/>
<end position="75"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="83"/>
<end position="86"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="88"/>
<end position="93"/>
</location>
</feature>
<feature type="turn" evidence="5">
<location>
<begin position="100"/>
<end position="102"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="118"/>
<end position="124"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="141"/>
<end position="149"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="160"/>
<end position="162"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="171"/>
<end position="175"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="176"/>
<end position="178"/>
</location>
</feature>
<feature type="turn" evidence="5">
<location>
<begin position="187"/>
<end position="192"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="199"/>
<end position="201"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="204"/>
<end position="206"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="209"/>
<end position="211"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="221"/>
<end position="223"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="243"/>
<end position="247"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="251"/>
<end position="260"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="263"/>
<end position="267"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="273"/>
<end position="275"/>
</location>
</feature>
<feature type="turn" evidence="5">
<location>
<begin position="276"/>
<end position="278"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="279"/>
<end position="281"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="283"/>
<end position="295"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="298"/>
<end position="300"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="305"/>
<end position="307"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="310"/>
<end position="314"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="319"/>
<end position="321"/>
</location>
</feature>
<feature type="turn" evidence="11">
<location>
<begin position="323"/>
<end position="325"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="327"/>
<end position="330"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="332"/>
<end position="334"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="338"/>
<end position="348"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="351"/>
<end position="355"/>
</location>
</feature>
<feature type="turn" evidence="5">
<location>
<begin position="356"/>
<end position="359"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="361"/>
<end position="369"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="377"/>
<end position="385"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="390"/>
<end position="393"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="395"/>
<end position="399"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="404"/>
<end position="406"/>
</location>
</feature>
<feature type="turn" evidence="5">
<location>
<begin position="422"/>
<end position="424"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="425"/>
<end position="430"/>
</location>
</feature>
<feature type="strand" evidence="11">
<location>
<begin position="437"/>
<end position="439"/>
</location>
</feature>
<feature type="turn" evidence="5">
<location>
<begin position="441"/>
<end position="443"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="452"/>
<end position="458"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="463"/>
<end position="472"/>
</location>
</feature>
<feature type="turn" evidence="5">
<location>
<begin position="476"/>
<end position="478"/>
</location>
</feature>
<feature type="turn" evidence="5">
<location>
<begin position="481"/>
<end position="483"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="486"/>
<end position="490"/>
</location>
</feature>
<feature type="strand" evidence="11">
<location>
<begin position="498"/>
<end position="500"/>
</location>
</feature>
<feature type="strand" evidence="11">
<location>
<begin position="502"/>
<end position="507"/>
</location>
</feature>
<feature type="strand" evidence="11">
<location>
<begin position="512"/>
<end position="516"/>
</location>
</feature>
<feature type="helix" evidence="11">
<location>
<begin position="524"/>
<end position="526"/>
</location>
</feature>
<feature type="strand" evidence="11">
<location>
<begin position="527"/>
<end position="536"/>
</location>
</feature>
<feature type="strand" evidence="11">
<location>
<begin position="538"/>
<end position="540"/>
</location>
</feature>
<feature type="strand" evidence="11">
<location>
<begin position="559"/>
<end position="561"/>
</location>
</feature>
<feature type="strand" evidence="11">
<location>
<begin position="577"/>
<end position="580"/>
</location>
</feature>
<feature type="strand" evidence="11">
<location>
<begin position="588"/>
<end position="597"/>
</location>
</feature>
<feature type="strand" evidence="11">
<location>
<begin position="601"/>
<end position="603"/>
</location>
</feature>
<feature type="strand" evidence="11">
<location>
<begin position="608"/>
<end position="610"/>
</location>
</feature>
<feature type="strand" evidence="11">
<location>
<begin position="613"/>
<end position="616"/>
</location>
</feature>
<feature type="strand" evidence="11">
<location>
<begin position="626"/>
<end position="631"/>
</location>
</feature>
<feature type="strand" evidence="11">
<location>
<begin position="633"/>
<end position="636"/>
</location>
</feature>
<feature type="strand" evidence="11">
<location>
<begin position="638"/>
<end position="643"/>
</location>
</feature>
<feature type="strand" evidence="11">
<location>
<begin position="654"/>
<end position="658"/>
</location>
</feature>
<feature type="helix" evidence="11">
<location>
<begin position="666"/>
<end position="669"/>
</location>
</feature>
<feature type="helix" evidence="11">
<location>
<begin position="722"/>
<end position="735"/>
</location>
</feature>
<feature type="strand" evidence="11">
<location>
<begin position="798"/>
<end position="803"/>
</location>
</feature>
<feature type="strand" evidence="11">
<location>
<begin position="805"/>
<end position="809"/>
</location>
</feature>
<feature type="strand" evidence="11">
<location>
<begin position="817"/>
<end position="827"/>
</location>
</feature>
<feature type="strand" evidence="11">
<location>
<begin position="838"/>
<end position="843"/>
</location>
</feature>
<feature type="strand" evidence="11">
<location>
<begin position="858"/>
<end position="861"/>
</location>
</feature>
<feature type="strand" evidence="11">
<location>
<begin position="867"/>
<end position="870"/>
</location>
</feature>
<feature type="strand" evidence="11">
<location>
<begin position="881"/>
<end position="890"/>
</location>
</feature>
<feature type="strand" evidence="11">
<location>
<begin position="896"/>
<end position="901"/>
</location>
</feature>
<feature type="helix" evidence="11">
<location>
<begin position="902"/>
<end position="908"/>
</location>
</feature>
<feature type="strand" evidence="11">
<location>
<begin position="910"/>
<end position="913"/>
</location>
</feature>
<feature type="strand" evidence="11">
<location>
<begin position="918"/>
<end position="931"/>
</location>
</feature>
<feature type="strand" evidence="11">
<location>
<begin position="940"/>
<end position="944"/>
</location>
</feature>
<feature type="helix" evidence="6">
<location>
<begin position="953"/>
<end position="979"/>
</location>
</feature>
<feature type="turn" evidence="10">
<location>
<begin position="1003"/>
<end position="1005"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="1009"/>
<end position="1011"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="1014"/>
<end position="1016"/>
</location>
</feature>
<feature type="helix" evidence="8">
<location>
<begin position="1020"/>
<end position="1022"/>
</location>
</feature>
<feature type="strand" evidence="8">
<location>
<begin position="1023"/>
<end position="1031"/>
</location>
</feature>
<feature type="strand" evidence="8">
<location>
<begin position="1033"/>
<end position="1043"/>
</location>
</feature>
<feature type="strand" evidence="7">
<location>
<begin position="1046"/>
<end position="1048"/>
</location>
</feature>
<feature type="strand" evidence="8">
<location>
<begin position="1050"/>
<end position="1057"/>
</location>
</feature>
<feature type="helix" evidence="8">
<location>
<begin position="1065"/>
<end position="1078"/>
</location>
</feature>
<feature type="strand" evidence="8">
<location>
<begin position="1089"/>
<end position="1093"/>
</location>
</feature>
<feature type="strand" evidence="8">
<location>
<begin position="1095"/>
<end position="1098"/>
</location>
</feature>
<feature type="strand" evidence="8">
<location>
<begin position="1100"/>
<end position="1104"/>
</location>
</feature>
<feature type="helix" evidence="8">
<location>
<begin position="1111"/>
<end position="1117"/>
</location>
</feature>
<feature type="strand" evidence="9">
<location>
<begin position="1119"/>
<end position="1121"/>
</location>
</feature>
<feature type="helix" evidence="8">
<location>
<begin position="1133"/>
<end position="1152"/>
</location>
</feature>
<feature type="strand" evidence="4">
<location>
<begin position="1154"/>
<end position="1156"/>
</location>
</feature>
<feature type="helix" evidence="8">
<location>
<begin position="1162"/>
<end position="1164"/>
</location>
</feature>
<feature type="strand" evidence="8">
<location>
<begin position="1165"/>
<end position="1167"/>
</location>
</feature>
<feature type="strand" evidence="8">
<location>
<begin position="1173"/>
<end position="1175"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="1181"/>
<end position="1183"/>
</location>
</feature>
<feature type="turn" evidence="8">
<location>
<begin position="1185"/>
<end position="1187"/>
</location>
</feature>
<feature type="strand" evidence="12">
<location>
<begin position="1190"/>
<end position="1192"/>
</location>
</feature>
<feature type="strand" evidence="8">
<location>
<begin position="1194"/>
<end position="1198"/>
</location>
</feature>
<feature type="helix" evidence="8">
<location>
<begin position="1200"/>
<end position="1202"/>
</location>
</feature>
<feature type="helix" evidence="8">
<location>
<begin position="1205"/>
<end position="1210"/>
</location>
</feature>
<feature type="helix" evidence="8">
<location>
<begin position="1215"/>
<end position="1230"/>
</location>
</feature>
<feature type="turn" evidence="8">
<location>
<begin position="1236"/>
<end position="1239"/>
</location>
</feature>
<feature type="helix" evidence="8">
<location>
<begin position="1242"/>
<end position="1250"/>
</location>
</feature>
<feature type="helix" evidence="8">
<location>
<begin position="1263"/>
<end position="1272"/>
</location>
</feature>
<feature type="helix" evidence="8">
<location>
<begin position="1277"/>
<end position="1279"/>
</location>
</feature>
<feature type="helix" evidence="8">
<location>
<begin position="1283"/>
<end position="1290"/>
</location>
</feature>
<feature type="helix" evidence="12">
<location>
<begin position="1291"/>
<end position="1293"/>
</location>
</feature>
<feature type="helix" evidence="8">
<location>
<begin position="1298"/>
<end position="1301"/>
</location>
</feature>
<feature type="turn" evidence="10">
<location>
<begin position="1303"/>
<end position="1305"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="1307"/>
<end position="1309"/>
</location>
</feature>
<evidence key="1" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1I44"/>
</source>
</evidence>
<evidence key="2" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1IR3"/>
</source>
</evidence>
<evidence key="3" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1IRK"/>
</source>
</evidence>
<evidence key="4" type="ECO:0000244">
<source>
<dbReference type="PDB" id="2AUH"/>
</source>
</evidence>
<evidence key="5" type="ECO:0000244">
<source>
<dbReference type="PDB" id="2HR7"/>
</source>
</evidence>
<evidence key="6" type="ECO:0000244">
<source>
<dbReference type="PDB" id="2MFR"/>
</source>
</evidence>
<evidence key="7" type="ECO:0000244">
<source>
<dbReference type="PDB" id="2Z8C"/>
</source>
</evidence>
<evidence key="8" type="ECO:0000244">
<source>
<dbReference type="PDB" id="3BU3"/>
</source>
</evidence>
<evidence key="9" type="ECO:0000244">
<source>
<dbReference type="PDB" id="3ETA"/>
</source>
</evidence>
<evidence key="10" type="ECO:0000244">
<source>
<dbReference type="PDB" id="4XLV"/>
</source>
</evidence>
<evidence key="11" type="ECO:0000244">
<source>
<dbReference type="PDB" id="4ZXB"/>
</source>
</evidence>
<evidence key="12" type="ECO:0000244">
<source>
<dbReference type="PDB" id="5HHW"/>
</source>
</evidence>
<evidence key="13" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="18669648"/>
</source>
</evidence>
<evidence key="14" type="ECO:0000250"/>
<evidence key="15" type="ECO:0000250">
<source>
<dbReference type="UniProtKB" id="P15127"/>
</source>
</evidence>
<evidence key="16" type="ECO:0000255"/>
<evidence key="17" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU00159"/>
</source>
</evidence>
<evidence key="18" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU00316"/>
</source>
</evidence>
<evidence key="19" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU10028"/>
</source>
</evidence>
<evidence key="20" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10207053"/>
</source>
</evidence>
<evidence key="21" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10443650"/>
</source>
</evidence>
<evidence key="22" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10615944"/>
</source>
</evidence>
<evidence key="23" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10733238"/>
</source>
</evidence>
<evidence key="24" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10734133"/>
</source>
</evidence>
<evidence key="25" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10803466"/>
</source>
</evidence>
<evidence key="26" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11124964"/>
</source>
</evidence>
<evidence key="27" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11260230"/>
</source>
</evidence>
<evidence key="28" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11374898"/>
</source>
</evidence>
<evidence key="29" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11598120"/>
</source>
</evidence>
<evidence key="30" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11726652"/>
</source>
</evidence>
<evidence key="31" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12023989"/>
</source>
</evidence>
<evidence key="32" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12107746"/>
</source>
</evidence>
<evidence key="33" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12138094"/>
</source>
</evidence>
<evidence key="34" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12493740"/>
</source>
</evidence>
<evidence key="35" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12538626"/>
</source>
</evidence>
<evidence key="36" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12612081"/>
</source>
</evidence>
<evidence key="37" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12707268"/>
</source>
</evidence>
<evidence key="38" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12970295"/>
</source>
</evidence>
<evidence key="39" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="14690593"/>
</source>
</evidence>
<evidence key="40" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="1470163"/>
</source>
</evidence>
<evidence key="41" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="1472036"/>
</source>
</evidence>
<evidence key="42" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15161766"/>
</source>
</evidence>
<evidence key="43" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15489334"/>
</source>
</evidence>
<evidence key="44" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="1563582"/>
</source>
</evidence>
<evidence key="45" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="1607067"/>
</source>
</evidence>
<evidence key="46" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="1607076"/>
</source>
</evidence>
<evidence key="47" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16127460"/>
</source>
</evidence>
<evidence key="48" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16246733"/>
</source>
</evidence>
<evidence key="49" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16271887"/>
</source>
</evidence>
<evidence key="50" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16314505"/>
</source>
</evidence>
<evidence key="51" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16831875"/>
</source>
</evidence>
<evidence key="52" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16894147"/>
</source>
</evidence>
<evidence key="53" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16957736"/>
</source>
</evidence>
<evidence key="54" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17201797"/>
</source>
</evidence>
<evidence key="55" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="1730625"/>
</source>
</evidence>
<evidence key="56" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17344846"/>
</source>
</evidence>
<evidence key="57" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18278056"/>
</source>
</evidence>
<evidence key="58" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18767165"/>
</source>
</evidence>
<evidence key="59" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="1890161"/>
</source>
</evidence>
<evidence key="60" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19056263"/>
</source>
</evidence>
<evidence key="61" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19071018"/>
</source>
</evidence>
<evidence key="62" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19159218"/>
</source>
</evidence>
<evidence key="63" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19349973"/>
</source>
</evidence>
<evidence key="64" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19394223"/>
</source>
</evidence>
<evidence key="65" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19459609"/>
</source>
</evidence>
<evidence key="66" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="1963473"/>
</source>
</evidence>
<evidence key="67" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="2002058"/>
</source>
</evidence>
<evidence key="68" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="2040394"/>
</source>
</evidence>
<evidence key="69" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="2121734"/>
</source>
</evidence>
<evidence key="70" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="2168397"/>
</source>
</evidence>
<evidence key="71" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="2210055"/>
</source>
</evidence>
<evidence key="72" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="2211730"/>
</source>
</evidence>
<evidence key="73" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="2280779"/>
</source>
</evidence>
<evidence key="74" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="23302862"/>
</source>
</evidence>
<evidence key="75" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="2365819"/>
</source>
</evidence>
<evidence key="76" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="2369896"/>
</source>
</evidence>
<evidence key="77" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="2479553"/>
</source>
</evidence>
<evidence key="78" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="2544998"/>
</source>
</evidence>
<evidence key="79" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="27617429"/>
</source>
</evidence>
<evidence key="80" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="2777789"/>
</source>
</evidence>
<evidence key="81" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="2806055"/>
</source>
</evidence>
<evidence key="82" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="2834824"/>
</source>
</evidence>
<evidence key="83" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="2842060"/>
</source>
</evidence>
<evidence key="84" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="2859121"/>
</source>
</evidence>
<evidence key="85" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="2983222"/>
</source>
</evidence>
<evidence key="86" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="3101064"/>
</source>
</evidence>
<evidence key="87" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="3166375"/>
</source>
</evidence>
<evidence key="88" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="3283938"/>
</source>
</evidence>
<evidence key="89" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="3680248"/>
</source>
</evidence>
<evidence key="90" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7537849"/>
</source>
</evidence>
<evidence key="91" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7538143"/>
</source>
</evidence>
<evidence key="92" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7559478"/>
</source>
</evidence>
<evidence key="93" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7657032"/>
</source>
</evidence>
<evidence key="94" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7815442"/>
</source>
</evidence>
<evidence key="95" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7983039"/>
</source>
</evidence>
<evidence key="96" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8082780"/>
</source>
</evidence>
<evidence key="97" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8096518"/>
</source>
</evidence>
<evidence key="98" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8188715"/>
</source>
</evidence>
<evidence key="99" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8242067"/>
</source>
</evidence>
<evidence key="100" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8243830"/>
</source>
</evidence>
<evidence key="101" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8257688"/>
</source>
</evidence>
<evidence key="102" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8276809"/>
</source>
</evidence>
<evidence key="103" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8288049"/>
</source>
</evidence>
<evidence key="104" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8314008"/>
</source>
</evidence>
<evidence key="105" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8326490"/>
</source>
</evidence>
<evidence key="106" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8388389"/>
</source>
</evidence>
<evidence key="107" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8390949"/>
</source>
</evidence>
<evidence key="108" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8419945"/>
</source>
</evidence>
<evidence key="109" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8432414"/>
</source>
</evidence>
<evidence key="110" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8452530"/>
</source>
</evidence>
<evidence key="111" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8458533"/>
</source>
</evidence>
<evidence key="112" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8636294"/>
</source>
</evidence>
<evidence key="113" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8890729"/>
</source>
</evidence>
<evidence key="114" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8995282"/>
</source>
</evidence>
<evidence key="115" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8999839"/>
</source>
</evidence>
<evidence key="116" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9175790"/>
</source>
</evidence>
<evidence key="117" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9199575"/>
</source>
</evidence>
<evidence key="118" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9202395"/>
</source>
</evidence>
<evidence key="119" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9249867"/>
</source>
</evidence>
<evidence key="120" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9299395"/>
</source>
</evidence>
<evidence key="121" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9312016"/>
</source>
</evidence>
<evidence key="122" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9355755"/>
</source>
</evidence>
<evidence key="123" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9428692"/>
</source>
</evidence>
<evidence key="124" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9703342"/>
</source>
</evidence>
<evidence key="125" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="15489334"/>
</source>
</evidence>
<evidence key="126" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="2983222"/>
</source>
</evidence>
<evidence key="127" type="ECO:0000303">
<source ref="13"/>
</evidence>
<evidence key="128" type="ECO:0000305"/>
<evidence key="129" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="3166375"/>
</source>
</evidence>
<sequence length="1382" mass="156333" checksum="709A955660739066" modified="2010-10-05" version="4" precursor="true">
MATGGRRGAAAAPLLVAVAALLLGAAGHLYPGEVCPGMDIRNNLTRLHELENCSVIEGHL
QILLMFKTRPEDFRDLSFPKLIMITDYLLLFRVYGLESLKDLFPNLTVIRGSRLFFNYAL
VIFEMVHLKELGLYNLMNITRGSVRIEKNNELCYLATIDWSRILDSVEDNYIVLNKDDNE
ECGDICPGTAKGKTNCPATVINGQFVERCWTHSHCQKVCPTICKSHGCTAEGLCCHSECL
GNCSQPDDPTKCVACRNFYLDGRCVETCPPPYYHFQDWRCVNFSFCQDLHHKCKNSRRQG
CHQYVIHNNKCIPECPSGYTMNSSNLLCTPCLGPCPKVCHLLEGEKTIDSVTSAQELRGC
TVINGSLIINIRGGNNLAAELEANLGLIEEISGYLKIRRSYALVSLSFFRKLRLIRGETL
EIGNYSFYALDNQNLRQLWDWSKHNLTITQGKLFFHYNPKLCLSEIHKMEEVSGTKGRQE
RNDIALKTNGDQASCENELLKFSYIRTSFDKILLRWEPYWPPDFRDLLGFMLFYKEAPYQ
NVTEFDGQDACGSNSWTVVDIDPPLRSNDPKSQNHPGWLMRGLKPWTQYAIFVKTLVTFS
DERRTYGAKSDIIYVQTDATNPSVPLDPISVSNSSSQIILKWKPPSDPNGNITHYLVFWE
RQAEDSELFELDYCLKGLKLPSRTWSPPFESEDSQKHNQSEYEDSAGECCSCPKTDSQIL
KELEESSFRKTFEDYLHNVVFVPRKTSSGTGAEDPRPSRKRRSLGDVGNVTVAVPTVAAF
PNTSSTSVPTSPEEHRPFEKVVNKESLVISGLRHFTGYRIELQACNQDTPEERCSVAAYV
SARTMPEAKADDIVGPVTHEIFENNVVHLMWQEPKEPNGLIVLYEVSYRRYGDEELHLCV
SRKHFALERGCRLRGLSPGNYSVRIRATSLAGNGSWTEPTYFYVTDYLDVPSNIAKIIIG
PLIFVFLFSVVIGSIYLFLRKRQPDGPLGPLYASSNPEYLSASDVFPCSVYVPDEWEVSR
EKITLLRELGQGSFGMVYEGNARDIIKGEAETRVAVKTVNESASLRERIEFLNEASVMKG
FTCHHVVRLLGVVSKGQPTLVVMELMAHGDLKSYLRSLRPEAENNPGRPPPTLQEMIQMA
AEIADGMAYLNAKKFVHRDLAARNCMVAHDFTVKIGDFGMTRDIYETDYYRKGGKGLLPV
RWMAPESLKDGVFTTSSDMWSFGVVLWEITSLAEQPYQGLSNEQVLKFVMDGGYLDQPDN
CPERVTDLMRMCWQFNPKMRPTFLEIVNLLKDDLHPSFPEVSFFHSEENKAPESEELEME
FEDMENVPLDRSSHCQREEAGGRDGGSSLGFKRSYEEHIPYTHMNGGKKNGRILTLPRSN
PS
</sequence>
</entry>
<copyright>
Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
Distributed under the Creative Commons Attribution-NoDerivs License
</copyright>
</uniprot>